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GENERAL INTRODUCTION 
For many years it has been recognized that patients with impaired 
host defense mechanisms due to hemoproliferative malignancy or its 
treatment are subject to episodes of fulminating, often lethal 
bacterial infection. The proper management of these infections is a 
problem, because antimicrobial agents which are known to be effective 
in the normal host, lose, at least partially, their efficacy in these 
patients. Therapeutic failures occur despite the organisms usual 
sensitivity. As a consequence, the use of combinations of antimicrobial 
drugs have been recommended for presumptive treatment of these 
life-threatening infections when the identity and susceptibility of 
the causative bacteria are unknown. 
The high risk of infectious complications in these patients may be 
due to impairment of their defense mechanisms. This in turn is the 
consequence of the malignant process itself. The immune system and 
its functions are involved in many aspects of malignancies, especially 
in hematological malignancies. These each have a characteristic 
pattern of immunodeficiencies. For example, hematological malignancies 
may suppress humoral and cellular immunity and cause neutropenia or 
an impaired neutrophil function. Also the antineoplastic therapy by 
radiation and/or chemotherapeutic agents, interferes with specific and 
nonspecific host defense functions. 
Several factors usually contribute simultaneously to the impairment of 
host defense in cancer patients. These include the underlying disease 
itself, invasive procedures and/or the antineoplastic therapy. As a 
result, a clear understanding of the relation between the efficacy of 
antimicrobial therapy and specific defects in host defense mechanisms 
is impossible. The critical role of individual host defense factors 
in the process of recovery during antimicrobial therapy can only be 
established in experimental infection. Two questions arise. To what 
extent does the susceptibility to infections and the efficacy of 
antimicrobial therapy depend on host defense mechanisms? Secondly, 
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can lack of host defense functions be partially compensated by 
intensification of the antibiotic treatment schedule. Animal 
studies may contribute to a deeper understanding of the relation 
between specific gaps in host defense and efficacy of antimicrobial 
therapy. 
The purpose of our study~ and the subject of this thesis is, to 
investigate tl1e importance of intact host defense mechanisms for the 
success of antimicrobial treatment in experimental infections. Our 
studies have concentrated on deficiencies in host phagocytic activity, 
because leukocytes play a central role in the host's defense against 
infection. In rats and mice infections were produced by inoculation 
with Streptococcus pneumoniae and Lister7:a monocytogenes, respectively. 
These infectious agents were chosen because of the fact that the 
course of infection and the defense mechanisms of the host are 
completely different in both models: 
- Intrabronchial inoculation of S. pneumoniae, an obligatory extra-
cellular parasite, results in an acute inflammatory response and a 
rapidly-spreading pneumonia with extensive pulmonary lesions. Host 
defense against S. pneumoniae depends on phagocytosis by polymorpho-
nuclear leukocytes (PMN). Without the presence of specific antibodies 
certain complement components act as opsonins. The spleen participates 
in clearing pneumococci from the blood. 
- Intravenous inoculation of L. monocytogenes~ a facultative intra-
cellular parasite that can survive and multiply in macrophages 
particularly in the spleen and liver, results in a chronic infection. 
Host resistance to L. monocytogenes depends on T-cell mediated 
immunity resulting in activation of macrophages, the target cells of 
Listeria. 
The host-bacteria relationship is relatively well-understood, but 
completely different in these experimental infection models. This 
enabled us to evaluate the change in efficacy of antimicrobial 
treatment as a function of selective elimination of several forms of 
host defense. 
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Chapters 1 through 3 describe the effect of impaired phagocytosis of 
S. pneumoniae by PMN upon the course of the infection and the efficacy 
of antimicrobial treatment of pneumococcal pneumonia in rats. Chapter 
1 and chapter 2 deal with the activity of penicillin therapy in this 
model. In chapter 3 several aspects of clindamycin therapy were 
examined. 
Another form of impaired host defense to pneumococcal infection we 
studied, was the removal of the spleen. In rats with pneumococcal 
bacteremia we studied the effect of splenectomy upon the course of the 
infection and the outcome of penicillin treatment. The results of 
these studies are reported in chapter 4. 
Chapter 5 describes the effect of impaired T-cell mediated immune 
functions upon the course of infection and the efficacy of ampicillin 
treatment in mice with infection caused by Listeria monocytogenes. 
The results of rifampicin treatment in this model are reported in 
the appendix. 
Finally a general discussion of the results of our experimental 
studies is presented in chapter 6. 
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Chapter 1 
EFFICACY OF ANTIMICROBIAL THERAPY IN EXPERIMENTAL RAT PNEUMONIA: 
EFFECTS OF IMPAIRED PHAGOCYTOSIS* 
Irma A.J.M. Bakker-Woudenberg, J.Y.T. de Jong-Hoenderop, and 
M.F. Michel 
Department of Clinical Microbiology and Antimicrobial Therapy~ 
Erasmus University Rotterdam~ The Netherlands 
The importance of intact host defense mechanisms for successful 
antimicrobial therapy was investigated in an animal model. Recovery 
from lobar pneumococcal pneumonia as a result of penicillin therapy 
was studied in normal rats and in rats treated with cobra venom factor. 
This factor was used to selectively suppress the phagocytosis of 
pneumococci as a result of complement depletion. Although complete 
recovery from the infection occurred in normal rats after appropriate 
penicillin therapy, this was not the case in cobra venom factor-treated 
rats. Within the limitations of this study, evidence is presented for 
loss of antibiotic activity as a consequence of impaired phagocytosis. 
Introduction 
Severe infections frequently occur in patients with hemoproliferative 
malignancies (5, 13, 15, 18, 19). They may be difficult to cure, as 
antimicrobial agents which are effective in normal hosts appear to 
have lost, at least in part, their efficacy in these patients. The high 
risk of infections in patients with malignancies may be due to an 
impairment of host defense mechanisms as a consequence of the malignant 
process itself or of the antineoplastic therapy (chemotherapy or radio-
therapy), or both. It is known that both factors may suppress specific 
*Infection and Immunity (1979) 25, 366-375. 
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and nonspecific host defense mechanisms, including cellular immunity 
(7, 8, 17, 22), antibody formation (7, 17, 22, 36), and the number or 
function of granulocytes (6, 7, 17, 26). Usually several factors 
contribute simultaneously to the impairment of host defense in cancer 
patients. The critical role of individual host defense factors in the 
process of recovery during antimicrobial therapy can only be 
established in experimental infection. In the present study several 
aspects of antimicrobial therapy of experimental pneumococcal pneumo-
nia in normal rats and in rats with impaired phagocytosis were 
examined. Phagocytosis was impaired by complement depletion by using 
injections of cobra venom factor (CVF). This model permits the study 
of the role of the host defense factors in the process of recovery 
during antimicrobial therapy. 
Materials and Methods 
~gi~~!~ 
Female R-strain albino rats (inbred strain specific pathogen free; 15 
weeks old; weight, 180 to 210 g; bred in the Laboratory Animals Center 
of the Erasmus University Rotterdam) were used in all experiments. 
£~£~~!i~ 
A St~eptococcus pneumoniae type III strain isolated from a clinical 
case was used in all experiments. The minimal inhibitory concentration 
for penicillin was 0.024 ~g/ml (tube dilution test). The virulence 
of the bacteria was maintained by passage in rats every 2 months and 
storage at -70°C in Todd-Hewitt broth (Oxoid) with 10% glycerol 
(Merck). 
Eg~~!~gi~ 
Experimental pneumonia was produced in the following manner. The rats 
were anesthetized with Hypnorm (Duphar) and pentobarbital. The left 
main stem bronchus was intubated, and the left lobe of the lung was 
inoculated with a suspension of 6 x 107 S. pneumoniae type III cells 
in a volume of 0.02 ml. To estimate the severity of the resulting 
pneumonia, five animals were observed during the entire course of 
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infection. In addition, dissections were made of groups of five 
animals at different intervals after inoculation, namely at 36, 84 and 
108 h on rats who received no antibiotic therapy and at 36, 84 and 
132 h on antibiotic-treated rats. 
Parameters for the severity of the resulting pneumonia were as follows: 
roentgenogram of the chest, total body weight, rectal temperature, 
macroscopic examinations of the lesion in the left lobe of the lung, 
weight of the left lobe of the lung, quantitation of the number of 
viable bacteria in the left lobe and the four right lobes of the lung, 
and cultures of blood and pleural fluid. 
hi~.!:~J:~g:z:: 
Lungs were fixed by injecting the trachea with 10% Formalin under a 
constant pressure to reexpand the lungs. The specimens were. then dehy-
drated in ethanol and toluol, imbedded in paraffin, sectioned, and 
stained with hematoxylin-eosin or by the Gram stain technique. 
~~.!:f~~E£~i~1-.!:!~~.!:~~~.!: 
The sodium salt of penicillin G in aqueous solution was injected intra-
muscularly into the thigh muscles of the rear legs. Every 12 h a dose 
of 2 mg/kg of body weight was administered. Nine injections were given, 
the first dose at 36 h after inoculation of the pneumococci . 
.!:!~~.!:~~~~-~i!~_£Y[ 
The venom of the cobra (Naja naja siamensis) was purified and kindly 
supplied by I.J .C. Wilschut (Cell Tissue Kinet., in press)". Rats--· were 
injected intraperitoneally 14 times with equal doses of CVF 
(0,7 units/kg of body weight). The first dose was administered at the 
time of pneumococcal inoculation, followed by five doses every 8 h and 
eight doses every 12 h. To determine complement depletion in vivo, rats 
were bled at several times during CVF treatment by orbital puncture. 
Sera were tested by an assay of complement hemolytic activity and an 
assay for complement component C3. 
~~~~l-~£E_££~E1~~~~E-~~~£1Y.!:i~-~~£i~i!l 
The sera were tested in a mixture containing 0.2 ml of sheep erythrocytes 
(10 7 cells, sensitized with hemolysin), 0.2 ml of serially diluted serum, 
J 3 
and 0.8 ml of Verona! buffer (pH 7.2; Oxoid). After incubation for 
60 min at 37°C, the mixture was centrifuged for 10 min at 1,300 x g, 
and the release of hemoglobin in the supernatant was recorded at 
413 nm in a Zeiss spectrophotometer. Controls included 100 and 0% 
lysis (guinea pig complement and Verona! buffer, respectively, instead 
of rat serum). The data derived from this assay were presented as 50% 
complement hemolysis units per milliliter, corresponding to the 
reciprocal of the serum dilution that gave 50% hemolysis. 
~~~~y_£~E-~£~E!~~~~E-~~~E£~~~E-~~ 
Serum C3 concentration was measured by the rocket immunoelectrophoresis 
technique of Laurel!, with some modifications (Wilschut, in press). 
Briefly, to avoid blunt precipitate peaks, the serum samples were 
carbamylated with 2 M potassium cyanate for 1 h at 37°C. To give a 
more precise measurement of the C3 concentration, the area enclosed 
by the precipitation peak was determined. Rabbit anti-rat C3 serum was 
purchased from Nordic Immunological Laboratories, Tilburg, The 
Netherlands. 
iB_YiE!~_Eb~g£SYE£~i~ 
A mixture of 7 x 108 washed pneumococci and I ml of rat serum was 
tumbled gently at 14 rpm for 30 min at 37°C. After opsonization, the 
mixture was kept for 2 h at 4°C, which was followed by centrifugation 
of the pneumococci at 3,500 x g for 10 min at 4°C. A leukocyte 
suspension was obtained from rat peritoneal washings 21 h after 
intraperitoneal injection of 4.5 ml of thioglycolate (Difco 
Laboratories). The peritoneal cells were washed two times in Hanks 
bovine albumin-glucose solution (33) and pelleted at 300 x g for 
10 min at 4°C. Eighty-six percent of the leukocytes were polymor-
phonuclear leukocytes (PMN). In the phagocytic test, 7 x 108 
opsonized pneumococci and 7 x 107 leukocytes were tumbled gently at 
14 rpm and 37°C in a total volume of 0.3 ml of buffer in polypropylene 
tubes (Falcon Plastics). (The buffer contained 0.14 M NaCl, 5 mM KCl, 
0.4 mM Mgso4 .7H2o, 0.5 mM MgC12.6H20, 1.3 mM CaC12 , 0.4 mM Na2HPo4 .IZH20, 
0.4 mM KH2Po4 , 5.6 mM glucose, and 4 roM NaHC03). After 30 min 
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phagocytosis was stopped by dilution in cold buffer (see above). The 
cells were centrifuged at 25 x g for 10 min at 4°C and washed to remove 
most of the extracellular bacteria. The leukocytes were then examined 
under a microscope in Gram-stained smears. A total of 400 leukocytes 
were observed, and the percentage of PMN containing pneumococci was 
calculated. Next, the average number of pneumococci per 100 PMN was 
estimated. The percent phagocytosis was calculated from the percentage 
of PMN containing pneumococci and the average number of pneumococci per 
cell. For instance, when 68% of the leukocytes contained pneumococci 
with an average of six pneumococci per cell, we calculated a total 
number of 1,632 pneumococci per 400 leukocyte~- The estimation of the 
total number of pneumococci per 400 leukocytes, as seen after 
opsonization with normal rat serum, was called 100% phagocytosis. 
Results 
~~~Ef~~gE~1_Eg~~~£gf~ 
After inoculation of the rats with 6 x 107 pneumococci, pneumonia 
developed within 24 h. Initially the infection was confined to the 
left lobe of the lung. By 108 h the pulmonary lesion involved the 
entire left lobe, and the infection was spreading to the right lobes. 
No spontaneous recovery occurred in untreated rats. During the course 
of the infection total body weight decreased constantly (Fig. IA), 
and rectal temperature decreased below normal after an initial rise 
(Fig. IB). The presence of an inflammatory response in the left lobe 
of the lung can be seen in a roentgenogram of the chest (Fig. 2B). 
Within the duration of our experiments no animals died spontaneously 
from infection. The animals were sacrificed at 36, 84, and 108 h after 
initiation of infection, and data are presented in Fig. lC through F. 
In these figures each point represents one animal. The involvement of 
the lung tissue in the infectious process was reflected by a 
proportional increase in weight (up to sixfold) of the left lobe of 
the lung (Fig. IC). At 108 h the pulmonary lesion was very extensive. 
During the course of infection, the number of pneumococci cultured 
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Fig. 1. C01use of pneumonia in noX'!lla"l rats after inocu"lation with 6 x 107 
type III pneumococci. (A) Tota"l body weight "loss (percentage) of five Pats 
during infection. (B) Recta"l temperatux-e of five rats d.uring infection 
(normal, temperature, 37.4 '!:.. 0.34°C). The fo"l"looing determinations wel"e made 
aftel" sacl"ifieing 15 rats in groups of 5. (C) Weight of the "left "lobe of 
the "lung (n.ol"ma"lweight, 0.6 '!:.. 0.15 g). {D) Number of viab"le pneumococcd in 
the left lobe of the lung. (E) NUmber of viable pneumoaoaei per milliliter 
of blood. (F) Culture of pleural fluid. 
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IFig. 2. {A) Chest roentgenograms of normal rats. (B) and {C) Chest roentgenograms 
of rats who developed pneumonia 3 days after inoculation with 6 x 107 type III 
pneumococci. {B) Untreated rats. {C) CVF-treated rats. 
from the left lobe of the lung increased and reached an average number 
of 6 x 109 bacteria at 108 h (Fig. 1D). Sooner or later the pneumonia 
caused a pneumococcal invasion of the bloodstream and pleural cavity. 
At 108 h this was reflected by positive cultures of blood and pleural 
fluid in all animals (Fig. lE and F). A control eh~eriment revealed 
that the technique of intubation itself did not influence total body 
weights or rectal temperatures. 
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B 
Fig. 3. Sections of the left lobes of the lungs from rats inoaUZated with 
type III pneumococci. {A) Section stained with hemato:x:ylin-eosin (xl6). At 
the mmogi?i of the lesion in the edeJJia zone there are few PMN in the aZveoli. 
More to the center of the lesion are edema-filled alveoli containing many 
PMN. In the eenter of the lesion zone of advanced consoUdation~ aZ.veoli are 
paaked with PMN. (B) Section stained with Gram stain (x400). AZ.veoli contain 
PMN and pneumococci~ many of wh:ich have aZready been phagocytized by PM.V. 
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Fig. 4. Action of penicillin (2 mg/kg per 12 h~ starting at 36 h) upon the course 
of pneumonia in normal rats afte:t> inocu'lation with 6 x 107 type III pneumococci. 
(A) Total body weight loss (percentage) of five rats during infection. (B) Rectal 
temperature of five rats dv.rin.g infection (no'l'maZ temperature:. 3?.4:!:.. 0.34°CJ. 
The following determinations were made after sacrificing 15 rats in groups of 5. 
(C) Weight of the left lobe of the Zung (normal weight, 0.6 "!:._ 0.15 g). (D) Number 
of viable pneumococci in the left lobe of the lung. (E) Number of viabZe pneumo-
cocci per miUi'liter of blood. {F) CuZ.ture of pZ.eu:.t'aZ. fluid. 
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hi:~.!:£1£SZ 
The histological studies of the pulmonary lesion revealed that no lung 
abscesses were present. Neutrophils predominated in the lesion, and 
phagocytosis of pneumococci by PMN was observed in the alveoli (Fig. 3). 
eg.;i£i~.!:i:E_.!:h~EeEz 
Penicillin therapy with repeated injections of 2 mg/kg per 12 h was 
begun 36 h after the initiation of infection. Figures 4A through F 
show that antibiotic therapy was successful in normal rats. After an 
initial decrease the total body weight increased again (Fig. 4A). 
Rectal temperature normalized after an initial increase (Fig. 4B). 
The spreading lesion was promptly arrested, as shown by the moderate 
increase in weight of the left lobe of the lung (Fig. 4C). At 
132 h all cultures of lungs, blood, and pleural fluid were sterile 
(Fig. 4D through F). 
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Table I. Opsonic activities of sePa fPom 
normal rats and rats treated with CVFa 
Preincubation medium % phagocy-tosis 
Norm.:~l rat serum undi 1 uted 
HBGb 
He.:~ted norm.:~l r.:~t serum (56°C 
for 30 min) 
C3-deficient rat c serum 
100 
2 
18 
43 
a Type Ill pneumococci were pre incubated ; ' sev-
era 1 medi.:~ aod .:~dded to the phagocytic system 
(see text) • 
b H BG, Hanks bovine albumin-glucose solution ( 32) 
c Obt.:~ined from CVF-treated rats (see text). 
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Fig. 5. Effect of CVF (0.7 units/kg) on 
cir~AZating C3 levels in serum. Each point 
represents the mean value of four rats 
(+standard deviation). 
i~-~i~~-~~f~£E~_£f_gy~ 
Whole complement hemolytic activity in serum decreased to less than 2% 
of normal values after multiple injections of CVF (0,7 units/kg). 
Figure 5 shows that the total levels of circulating C3 after the same 
CVF treatment fell to less than 3% of the pretreatment level. 
igf1~~gs~_Qf_gY!_£g_Eg~g££Y!£~i~_ig_~i!!£ 
Pneumococci were effectively phagocytized by PMN after opsonization 
with normal rat serum (100%). The opsonic activity of the serum 
decreased to 18% upon heating at 56°C for 30 min and was reduced to 
43% when rats were treated with CVF, as evidenced by an impaired 
phagocytosis of pneumococci (Table I). 
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Fig. 6. Course of pnewnonia in CVF-tr-eated rats after inoculat:ion with 6 x 1l 
~pe III pneumococci. (A) Total body weight loss (percentage) of five rats 
dUring infection. {B) Rectal temperature of five rats during infection (nor.mal 
temperature~ 37.4 ~ 0.34°C). The following determinations were made after 
sacrificing 15 rate in groups of 5. (C) Weight of the left lobe of the lung 
(normal weight, 0.6!.. 0.15 g). (D) Number- of viable pneumococci in the left 
lobe of the lung. (E) Mumber of viable pneumococci per milliliter of blood. 
(F) Culture of pleural fluid. 
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E~~~~~i~-~~-g~:EE~~!~~-E~!~ 
With the same number of pneumococci used in previous experiments 
pneumonia was produced in CVF-treated rats (Fig. 6A through F). The 
course of this infection was more severe in comparison with the 
infection in normal animals (Fig. 1A through F). As appeared from the 
roentgenograms, the pneumonia spread more rapidly in the CVF-treated 
rats (Fig. 2C) than in the rats not treated with CVF (Fig. 2B). No 
spontaneous recovery occurred in CVF-treated rats, as evidenced by a 
continuous decrease in total body weights (Fig. 6A) and rectal 
temperatures. The values of the latter finally fell far below normal 
(Fig. 6B). Lungs taken from animals sacrificed at 36, 84, and 108 h 
after inoculation also revealed more severe pneumonia as a result of 
CVF treatment. The pulmonary lesions were very extensive, as seen in 
the increase in weight (up to sevenfold) of the left lobe of the lung 
(Fig. 6C). By 108 h an average of 3 x 10 10 pneumococci were ~ultured 
from the left lobe (Fig. 6D)~ In early stages of the infection pneumo-
cocci were seen in the blood and pleural fluid (Fig. 6E and F), and 
by JOB h the average number of bacteria per milliliter of blood had 
increased to 2 x 106 • 
A control experiment revealed that the CVF treatment itself did not 
influence total body weights or rectal temperatures. 
~~Ei£12EiE_!h~EeEY_£f_gY!:EE~e!~~-EeE~ 
Repeated injections of penicillin (2 mg/kg per 12 h starting 36 h after 
initiation of infection) was unsuccessful in eradicating the pneumo-
coccal infection. There was also no increase in total body weights 
(Fig. 7A) and no normalization of rectal temperatures (Fig. 7B), and 
the cultures of lungs, blood, and pleural fluid remained positive 
(Fig. 7C through F). When the animals were sacrificed, the pneumonia 
was still actively spreading. 
Discussion 
The purpose of this study was to examine the efficacy of antimicrobial 
therapy in animals with selectively impaired host defense mechanisms. 
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Pneumonia and septicemia are the most common types of infections in 
compromised hosts (5, 14, 30) and major problems in patients with severe 
neutropenia (23). An experimental pneumococcal pneumonia in rats was 
chosen as an infection model, because the host-bacteria relationship 
in this model is relatively well understood (29, 33, 37, 39). The 
experimental pneumonia was characterized by a lobar consolidation as 
seen on the chest roentgenograms and at autopsy. Our histological 
studies of the pulmonary lesion revealed the same characteristics as 
described by Wood and Smith (42), except that there were no areas of 
abscess formation. In addition, bacteremia and extrapulmonary 
complications, such as pleurisy, were present as a rule. The pneumonia 
in the rats spread actively. Phagocytosis of pneumococci by PMN is the 
primary defense against this infection, and our histological results 
supported prior studies (42). However, phagocytosis alone was not 
sufficient for spontaneous recovery. To cure the infection, it was 
necessary to inject penicillin intramuscularly every 12 h at a dose of 
2 mg/kg of body weight, starting 36 h after initiation of the infection. 
This dose was chosen because previous experiments with lOwer doses 
revealed that 2 mg/kg of body weight was the minimal effective dose 
required for the recovery of rats. Penicillin therapy was started 36 h 
after inoculation since at that time the pneumonia was developed. This 
permitted us to study the role of one host defense factor in the process 
of recovery during penicillin therapy. The influence of a selectively 
impaired host defense on the efficacy of antimicrobial therapy was 
examined by impairing phagocytosis in rats. Because phagocytosis of 
encapsulated pneumococci occurs after opsonization of the bacteria (28), 
impairment of phagocytosis was accomplished by removing the opsonins. 
In the early preantibody phase of infection, C3 is the principal 
component involved in the opsonization process (31, 38). C3 is directly 
activated by pneumococci (11, 34, 40), followed by fixation of C3b on 
bacterial surfaces. Through complement receptor sites on the surface 
of PMN (12, 21) binding of pneumococci to PMN occurs, resulting in 
phagocytosis. 
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These observations in animals explain why phagocytosis of the pneumo-
cocci was impaired by the depletion of plasma C3. This depletion was 
realized by repeated injections of the rats with CVF. It has been 
demonstrated that this factor may cause prolonged depletion of plasma 
C3 in several species (9, 20, 24). In the present study low levels of 
C3 were also observed in the sera of CVF-treated rats. The opsonic 
capacity of these sera was also grossly deficient, as measured by 
in vitro phagocytosis of pneumococci by PMN. As expected from these 
in vitro experiments, CVF-treated rats appeared to be incapable of 
producing adequate phagocytosis of pneumococci in the alveoli. This 
was confirmed by the fact that the spreading of the pulmonary infection 
in CVF-treated rats was more rapid and extensive than in untreated 
rats. These data are in accordance with the observation that patients 
with abnormalities of the complement system, especially C3, suffer from 
recurrent pneumococcal infections (1, 2, 25). Grosset al. found that 
hypocomplementemia predisposes mice to bacterial pneumonia (16). 
Despite therapy with penicillin, CVF-treated rats did not show signs 
of recovery. As the same therapy was successful in untreated animals, 
it mus't be concluded that penicillin shows a complete loss of efficacy 
during treatment of an infection caused by susceptible organisms in 
animals with impaired phagocytosis. 
These data are in accordance with the findings of Smith and Wood, who 
reported that penicillin therapy of pneumococcal myositis lesions in 
irradiated mice was less effective than such therapy in normal mice 
(32). They concluded that the curative effect of penicillin was due to 
the combined effect of the dr'ug and the cellular defenses of the host. 
The same conclusion also resulted from experiments of Dale et al. with 
irradiated dogs (10). However, the interpretation of these results is 
hindered by the fact that radiation not only induces granulocytopenia 
but also damages other systems like erythropoiesis and thrombopoiesis, 
and so may cause untimely death of the animals (41). Experimental 
studies of BirO and Ivan (4), Trnka et al. (35), and Scott and Robson 
(27) revealed the effect of certain cancer chemotherapeutic agents 
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upon the efficacy of antimicrobial therapy. However, interpretation of 
these results is difficult because most cancer chemotherapeutic agents 
have multiple immunosuppressive actions both on B and T cells as well as 
on neutrophils. In this study, we suppressed host defense against the 
infectious organisms by an indirect and consequently selective way. 
Therefore, we may conclude that loss of activity of this penicillin 
treatment schedule results from selectively impaired phagocytosis of the 
infectious organisms. The total effect of antimicrobial therapy during 
an infection is the combined effect of the curative action of the 
antibiotic (penicillin in this case) in combination with the activity 
of the cellular defenses of the host (PMN in this case). If this 
hypothesis is correct, a lack of phagocytic functions of PMN might be 
compensated partially by an improved antibiotic treatment s~hedule, 
i.e. by increasing the dose or frequency of injections, or both. In a 
companion paper (3) observations related to the dose and administration 
schedule of penicillin in rats with impaired phagocytosis are reported. 
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Chapter 2 
EFFICACY OF ANTIMICROBIAl THERAPY IN EXPERIMENTAl RAT PNEUMONIA: 
PENICILLIN TREATMENT SCHEDULES IN RATS WITH IMPAIRED PHAGOCYTOSIS"* 
Irma A.J.M. Bakker-Woudenberg, A.L.E.M. van Gerwen, and M.F. Michel 
Department of Clinical Micr·obiology md Antimicrobial Therccpy~ 
Er•asrrrus University Rotter·da:rn~ The Netherlands 
Pneumococcal pneumonia in rats with intact host defense mechanisms 
could be successfully cured by penicillin. The efficacy of this 
antibiotic therapy was lost in cobra venom factor-treated rats which 
had selectively impaired phagocytic functions. In these animals the 
effect of penicillin therapy was improved by increasing the daily dose 
and the frequency of injections and by earlier initiation of the 
therapy. The efficacy of penicillin in the cobra venom factor-treated 
rats was restored either by markedly increasing the daily dose of 
penicillin or by increasing the daily dose in combination with a 
reduced interval of the penicillin injections. 
Introduction 
In another paper (1) it was shown that an experimental pneumococcal 
pneumonia in normal rats can be cured by penicillin. In rats with 
phagocytosis of the pneumococci by neutrophils selectively impaired, 
the infection could not be cured with the same amount of penicillin. 
These data are in accordance with the clinical findings that patients 
with impaired phagocytosis as a consequence of their malignancy or 
the administration of antitumor agents suffer from recurrent infections 
and often respond poorly to antimicrobial therapy (9). Because of the 
diminished efficacy of antimicrobial therapy, different antibiotic 
*Infection and Immunity (1979) 25, 376-387. 
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dosage schedules have been examined in these patients (4). In this 
study we investigated to.what extent the antimicrobial response in 
rats with selectively impaired phagocytosis can be improved by 
alterations in the antimicrobial treatment schedule. 
Materials and Methods 
g~~~al_~E~£~~ 
The production of lung infection and treatment with cobra venom factor 
(CVF) were performed as described in another paper (I). Five animals 
were observed during the course of infection in order to measure body 
weights and rectal temperatures. Animals were sacrificed in groups of 
five at 36, 84, and 132 h after inoculation in order to measure the 
weight of the left lobe of the lung, count the number of viable 
bacteria present in the left lobe of the lung, and culture blood and 
pleural fluid. 
~~5f~i£!£~i~!-5!~~E~~~E 
The sodium salt of penicillin G in aqueous solution was used. 
Individual doses of penicillin amounted to 2, 4, 24, 34, 44, and 
50 mg/kg of body weight. Penicillin injections were given either every 
12 or every 8 h intramuscularly into the thigh muscles of the 
rear legs. The first penicillin injection was given either 36 or 24 h 
after inoculation of pneumococci. The last injection was given 132 h 
after inoculation. 
e~ti£f£Ef£_~~~er 
Penicillin levels were estimated by a standard large-plate agar 
diffusion technique with Oxoid diagnostic sensitivity test agar and 
a StaphyZococc~s aureus strain as the indicator organism (2). The 
tests were performed with 200 ~1 of rat serum per test. Blood 
specimens for antibiotic assay were obtained by orbital puncture 
under light anesthesia. From each rat five blood samples were collected 
at different times after intramuscular injection of the antibiotic. 
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Results 
The effect of different penicillin dosage schedules upon the course of 
pneumococcal pneumonia in CVF-treated rats (Fig. 1 through 9) may be 
compared with the efficacy of penicillin at a dosage rate of 2 mg/kg 
per 12 h started at 36 h after inoculation of pneumococci into normal 
and CVF-treated rats (1). In all different treatment schedules, total 
body weight decreased constantly in some animals, whereas in other 
animals body weight remai~ed constant at a subnormal level during 
treatment (Fig. 1 through 9). All different treatment schedules 
eventually caused normalization of rectal temperatures. This was also 
the case in some of the rats who received penicillin at a rate of 
4 mg/kg per 12 h starting at 36 h (Fig. 2). These animals suffered 
from subnormal temperatures for several days during infection. When 
penicillin injections were started as early as 24 h after inoculation 
of pneumococci (Fig. I), bacteria were still cultured from the left 
lobe of the lung at 132 h. Similarly, when the dose of penicillin was 
doubled (Fig. 2), the lungs were not sterilized. Figures 5 through 7 
show the effect of three successive dosage schedules upon pneumonia 
in the CVF-treated rats; an increase in .dosage of at least 22 times 
(44 versus 2 mg) was needed to sterilize the lungs of most of the 
CVF-treated animals (Fig. 7). Other experiments (data not shown) 
revealed that a penicillin dosage of 50 mg/kg per 12 h starting at 
36 h was successful in clearing the lungs of all CVF-treated animals 
at 132 h. 
When the interval between the 2 mg/kg injections was shortened from 
12 to 8 h (Fig. 3), the lungs were not sterilized. This increase in 
frequency of injections from 12 to 8 h in combination with a doubled 
penicillin dose (4 mg/kg per 8 h) sterilized the lungs of only one of 
five animals (Fig. 4). Figures 8 and 9 show that a 17-fold increase 
(34 versus 2 mg) in penicillin dose was sufficient to sterilize the 
lungs when the interval between the injections was shortened from 
12 to 8 h. 
Intramuscular injections of penicillin doses of 34 and 50 mg/kg gave 
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Fig. 5. Action of peniciZ.Z.in at 24 mg/kg per 12 h stca>ting at 36 h upon the course 
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::_ 0.34°C). The following determinations were made after sacrific:ing 15 rats in 
groups of 5. (C) Weight of the left Wbe of the lung (normal weight, 0.6 ::!:_ 0.15 g). 
{D) Number of viable pneumococci in the left lobe of the lung. (E) Number of 
viabZe pn.ewnococ:ci per milliliter of blood. (F) Culture of pleuroal fl,uid. 
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rise to penicillin levels which differed in peak heights and times 
during which the penicillin concentration exceeded the minimal 
inhibitory-concentration of the pneumococcus (0.024 ug/ml); 
administration of 34 and 50 mg/kg gave peak concentrations of 49 and 
76 ug/ml, respectively, and the durations of detectable concentrations 
of penicillin (0.125 ug/ml) were 119 and 212 min, respectively 
(Fig. 10). Estimated minimal effective plasma concentrations of 
0.024 ug of penicillin per ml or greater were present for 134 and 250 
min, respectively. When the frequency of penicillin injections was 
increased, blood and pleural fluid became sterile in all rats at 84 h 
after initiation of infection (Fig. 3 and 4). However, penicillin at 
4 mg/kg per 12 h was only partially successful in clearing the 
infectious organisms from blood and pleural fluid (Fig. 2). On the 
other hand, a penicillin dose of 24 mg/kg per 12 h completely cleared 
blood and pleural fluid (Fig. 5). By advancing the penicillin 
treatment schedule of 2 mg/kg per 12 h by 12 h (starting at 24 instead 
of 36 h), the blood and pleural fluid of only some of the animals 
were cleared of pneumococci (Fig. 1). 
Discussion 
In another paper evidence was presented that penicillin therapy 
cured rats with pneumococcal pneumonia, but was ineffective in rats 
with selectively impaired phagocytosis (1). In this study we 
demonstrated that, in rats with impaired phagocytic function, the 
therapeutic effect of the penicillin therapy could be partially 
restored either by earlier initiation of the therapy or by 
increasing the dose or the frequency of the penicillin injec-
tions. 
Injection schedules of 50 mg/kg per 12 h or 34 mg/kg per 8 h, 
both starting 36 h after initiation of the infection in CVF-treated 
rats, equaled the success of the 2 mg/kg per 12 h dosage schedule 
starting at 36 h in rats with intact host defense mechanisms. That 
the minimal effective penicillin dose can be reduced when the 
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Fig. 6. Action of penici"ltin at 34 mg/kg per 12 h stax>ting at 36 h upon the course 
of the pneumonia in CVF-treated rats after inoculation with 6 x 107 type III pneu-
moc:occi. {A) Total body weight loss (percentage) of five rats during infection. 
(B) Rectal temperature of five rats during infection (no:t7!1al temperature" 3?.4 
'!:.. 0.34°CJ. The foUowing deter>minations were made after sacrific:ing 15 rats in 
groups of 5. (C) Weight of the left lobe of the lung (normal weight" 0.6 '!:.. 0.15 g). 
(D) Number of viable pnewnococc:i in the Zej't l-obe of the lung. (E) Nwnber of 
viabZe pneumocOcci per milliliter of blood. {F) Culture of pZeuroaZ f!uid. 
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Fig. 7. Action of penicillin at 44 mg/kg per 12 h starting at 36 h upon the cota>se 
of the pneumonia in CVF-treated rats after inoculation with 6 x 107 type III pneu-
mococci. (A) TotaZ body weight Z.oss (pereentage) of five rats during infection. 
(B) Rectal temperature of five rats du:ring infeetion (nomal temperatu::!'e;o 37.4 
t._ O.JtJCJ. The foZZOUJing determinations were rrade after sacrificing 15 rats in 
groups of 5. (C) Weight of the left lobe of the lung (normal weight~ 0.6 t._ 0.15 g). 
{D) Number> of viabZe pneumococci in the left lobe of the lung. (E) Nwriber of 
viabZe pnewnoc:occ:i per miZliliter of blood. (F) Cultuz>e of pZeu:t>aZ fluid. 
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Fig. 8. Action of peniciZ:Z.in at 24 mg/kg per 8 h starting at 36 h upon the course 
of the pneumonia in CVF-treated rats after inoeuZ.ation with 6 x 107 type III pneu-
mococci. (A) Total. body weight toss (percentage) of five rats during infection. 
(B) Rectal temperat"u:t>e of five rats during infection (norrraZ temperature, 37.4 
:!:_ 0.34°C). The foZ"loriJing determinations were made after sac:rificing 15 rats in 
groups of 5. (C) Weight of the Zeft lobe of the Zung (normal weight, 0.6 :!:_ 0.15 g). 
(D) Number of viabZ.e pneumoeocci in the Zeft Z.obe of the Zung. (E) Number of 
viabZ.e pneumococci per miUiZiter of bZ.ood. (F) Culture of pleural [Zuid. 
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Fig. 9. Action of penicillin at 34 mg/kg pel! 8 h stax>ting at 36 h upon the C:Ola"Se 
of the pneumonia in CVF-treated rats after inocuZ.ation with 6 x 107 type III pneu-
mococci. (A) Total- body weight loss (percentage) of five rats dUX>ing infection. 
(B) Rectal. temperature of five rats during infection (normal temperature3 37.4 
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groups of 5. {C) Weight of the left lobe of the Z.ung (normal weight~ 0. 6 !:_ 0.15 g). 
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Fig. 10. Serum concentrations of penicillin. Rats 
were injected intramuscularly with penicillin doses of 
2 mg/kg (---), 
34 mg/kg ( ..... ), or 
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Each point represents the mean value of five rats 
(~standard deviation). 
interval between the injections is shortened from 12 to 8 h may be 
explained from data on the plasma levels of the drug at varying times 
after intramuscular administration. Injections of 34 and 50 mg of 
penicillin per kg gave rise to drug levels which differed in height 
and time during which the antibiotic concentration exceeded the 
minimal inhibitory concentration of the pneumococcus. It might be 
concluded that improvement of the antibiotic treatment schedule 
obtained by increasing the penicillin dose or frequency of penicillin 
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injections or both can compensate at least in part for the impaired 
phagocytosis of pneumococci by polymorphonuclear leukocytes in 
CVF-treated rats. This is consistent with the hypothesis that the total 
effect of antimicrobial therapy during an infection is due to the come 
bined effect of the antimicrobial drug and the cellular defenses of the 
host. 
Brewin at al. (5) studied what beneficial effect varying doses of 
procaine penicillin G had on the treatment of hospitalized patients 
with pneumococcal pneumonia of varying severity. His conclusion was 
that there was no advantage in treating patients with massive dosages of 
penicillin. In this experimental study evidence was presented that 
animals with impaired host defense mechanisms benefit more from massive 
dosages of penicillin than from moderate dosages. 
When the interval between penicillin injections was reduced from 12 to 
8 h, pneumococci were cleared from blood and pleural fluid. This is in 
accordance with the findings of Schmidt and Walley, who tried various 
dosage regimens of penicillin against type I pneumococcal pneumonia in 
normal rats (I I). They found that administration of the antibiotic was 
most effective when it was given every 8 h. 
In the present study a considerable amount of penicillin was required 
to eradicate the pneumococci from the lungs of all CVF-treated animals. 
Experiments of Scott et al. revealed the loss of antimicrobial activity 
in cyclophosphamide-treated rats injected with several doses of 
gentamicin (12). Whether the loss of antibiotic activity resulted from 
impairment of a single host defense factor cannot be concluded from 
their study. Cyclophosphamide is not a selective immunosuppressive 
agent, but acts on T and B cells as well as on neutrophils. Also, the 
antibiotic therapy was instituted early after the onset of infection 
(2 h), when the role of host defense mechanisms in the infectious 
process is more difficult to evaluate. Our data in rats with 
selectively impaired phagocytosis are in accordance with the clinical 
findings concerning the effect of various dosage regimens of antibiotics 
against infections in cancer patients (4). In severe infections in these 
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patients, it is advisable to institute antimicrobial therapy immediately 
at the onset of infection (4, 8, 10). Based on clinical experience, 
Bodey and others have suggested that the results in antimicrobial 
therapy can be improved in neutropenic patients by administering 
combinations of antibiotics that have synergistic in vitro activity (3~ 
6, 7, 9, 10). In further studies several antibiotic combinations will 
be applied in this experimental infection model in rats with impaired 
host defense mechanisms. Infections with organisms other than the 
pneumococci will also be studied. 
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Chapter 3 
EFFICACY OF ANTIMICROBIAl THERAPY IN EXPERIMENTAl RAT PNEUMONIA: 
CLINDAMYCIN TREATMENT SCHEDULES IN RATS WITH IMPAIRED PHAGOCYTOSIS* 
Irma A.J.M. Bakker-Woudenberg, J.C. van de Berg, W.B. van Leeuwen, 
and M.F. Michel 
Department of Clinical ~crobiology and Antimicrobial Therapy~ 
Erasmus University Rotterdam~ The NetherlandS 
Pneumococcal pneumonia in rats with intact host defense mechanisms was 
successfully cured by clindamycin. In cobra venom factor-treated rats 
with impaired phagocytosis of pneumococci, the efficacy of the same 
clindamycin treatment was lost. In these rats the therapeutic effect of 
the clindamycin treatment was restored by a four-fold increase in dosage. 
The efficacy of clindamycin - in terms of minimal dosage and treatment 
schedule required for recovery of normal rats and rats with impaired 
host defense - differed from the efficacy of penicillin (described 
earlier). In vitro experiments showed that penicillin was not inactivated 
by homogenates of pneumococcal-infected lung tissue of cobra venom 
factor-treated rats. The serum levels of clindamycin were determined at 
different intervals after its administration, and compared to penicillin 
levels (described earlier). The duration of the periods where the 
antibiotic serum levels exceeded the minimal inhibitory concentration 
(MIC) for the pneumococci appear to be much longer after injection of 
clindamycin than of penicillin. Within the limits of this study evidence 
is presented for the superiority of clindamycin over penicillin in the 
treatment of experimental pneumococcal pneumonia in rats with impaired 
host defense. In these animals it is important to maintain prolonged 
inhibitory serum concentration of antibiotic. 
*In shortened version submitted for publication. 
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Introduction 
In previous papers it has been shown that an experimental pneumococcal 
pneumonia in normal rats was successfully cured by penicillin (2, 3). 
The efficacy of this antibiotic therapy was lost in cobra venom factor-
treated rats with impaired opsonization of pneumococci resulting in 
impaired phagocytosis. In these rats, the therapeutic effect of the 
penicillin therapy was restored by 25-fold increase in daily dosage, or 
by a combination of an increased daily dosage (17-fold) and a shortened 
interval between penicillin injections (every 8 h instead of every 
12 h). In the present study, the efficacy of clindamycin therapy was 
studied in norm.il rats and in rats with impaired phagocytosis. 
Materials and Methods 
~gim§!:b~ 
Female R-strain albino rats (inbred strain; specific pathogen free; 
14-16 weeks old; weight 180 to 210 g; bred in the Laboratory Animals 
Center of the Erasmus University Rotterdam) were used in all 
experiments. 
£!!~1:~Ei:~ 
A Streptoeoceus pneumoniae type III strain isolated from a clinical 
case was used in all experiments. The minimal bactericidal 
concentration of clindamycin was 0.024 ~g/ml (tube dilution test). 
The virulence of the bacteria was maintained by passage in rats 
every 4 months and by storage at -70°C in Todd-Hewitt broth (Oxoid) 
with 10% glycerol (Merck). 
tr~ef~~E-~f~~-~££E~-~~!!~~-f~E~£E 
Rats were treated with cobra venom factor (CVF) as described earlier 
(2). Rats were injected intraperitoneally 14 times with equal doses of 
CVF (0.7 units/kg of body weight). One unit of CVF amounted to 12 ~g 
of the purified material. The first dose was administered at the time 
of pneumococcal inoculation, followed by five doses at 8 hourly inter-
vals and eight doses at 12 hourly intervals. Assays for complement 
component C3 in sera of CVF-treated rats revealed that total levels of 
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circulating C3 fell to less than 3% of the pretreatment level (2). 
E~~~£~~~ 
Experimental pneumonia was produced as described earlier (2). Under 
anesthesia the left main stem bronchus was intubated, and the left 
. . . 6 o7 lobe of the lung was ~noculated w~th a suspens~on of x 1 
S. pneumoniae type III cells in a volume of 0.02 ml. Parameters for 
the severity of the pneumonia were: total body weight, rectal tempe-
rature, weight of the left lobe of the lung, quantification of the 
number of viable bacteria in the left lobe of the lung, and cultures 
of blood and pleural fluid. After inoculation of the rats with 
6 x 107 pneumococci, pneumonia developed initially in the left lobe 
of the lung. The course of pneumococcal pneumonia in CVF-treated 
rats was more severe than the infection in normal animals (2). The 
pneumonia spread more rapidly in the CVF-treated rats. 
~gfi~S!~£i~1_!!~~!~~~! 
Aqueous solutions of clindamycin (Dalacin C phosphate, Upjohn) were 
injected intramuscularly into the thigh muscles of the rear legs. 
Individual doses of clindamycin amounted to 2, 4 or 8 mg/kg of body 
weight. Nine clindamycin injections were given every 12 h, the first 
dose 36 h after inoculation of the pneumococci, the last dose 120 h 
after inoculation. 
E~nisi11i~-i~~£!iY~!i~g-~~~~Y 
Inactivation experiments were performed by adding 0.1 ml of the 
appropriate concentration of penicillin to 4 ml uninfected or pneumo-
coccal-infected lung homogenates. Final concentrations of penicillin 
were 1 and 10 ~g/ml. The infected left lobes of the lungs of normal 
rats and of CVF-treated rats were removed· and homogenized (each lobe 
in 20 ml of saline) three days after pneumococcal inoculation. The 
mixtures were tumbled gently at 14 rpm at 37°C. Immediately after 
mixing (0 h), and after I~ and 6 h incubation at 37°C, the mixtures 
were assayed against penicillin standards in normal lung homogenates 
(see antibiotic assay). 
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~~E~-~g£f£f£Ei£_1~~~12 
Serum antibiotic levels were determined after intramuscular injections 
of clindamycin. Individual doses of clindamycin amounted to 2 or 
8 mg/kg of body weight. Blood specimens for antibiotic assay were 
obtained by orbital puncture under light ether anesthesia. From each 
rat blood was collected at five different times after intramuscular 
injection of the antibiotic. 
~gEi£!~5!£_~~~2 
Clindamycin levels were estimated by a standard agar diffusion method 
(7) with some modifications: sensitivity test agar* and a Bacillus 
stearothermophiZus s·train as the indicator organism were used, and 
incubations were performed at 56°C. (Sensitivity of the assay system 
was 0.06 ~g/ml for clindamycin). Clindamycin hydrochloride (Upjohn) was 
used for preparation of standard solutions. Tests were performed with 
200 ~1 of rat serum per test. 
Results 
£1!g~~z~!g_£~~E~El-~f-~£~~1-E~E2-~E~-E~~~~~~~~~1-Eg~~£g!~ 
After pneumococcal inoculation of the rats, pneumonia developed as 
described earlier (2), in short: during the course of the infection 
total body weight decreased constantly and rectal temperature decreased 
below normal after initial rise. There was an increase in weight (up 
to sixfold) of the left lobe of the lung. Cultures of lungs, blood and 
pleural fluid were positive; by 108 h an average of 6 x 109 pneumo-
cocci were cultured from the left lobe of the lung, and the number of 
pneumococci cultured from the blood reached an average number of 
4 5 x 10 per milliliter. 
Repeated injections with 2 mg clindamycin per kg every 12 h starting 
36 h after the initiation of the infection was the minimal effective 
treatment required for the recovery of normal rats within 132 h 
(Fig. 1). Total body weights increased again, and rectal temperature 
*0.5% tryptone, 0.25% yeast extract, 0.1% glucose, 1.5% agar (Difco) 
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normalized (Fig. IA and IB). There was a moderate increase in weight 
of the left lobe of the lung (Fig. IC). This clindamycin treatment 
schedule could sterilize the lungs, blood and pleural fluid of all 
animals (Fig. ID trough IF). 
~1!~~~~i~-~h~E~EY_2f-f~:EE~~£~£_E~E~-~Eh_E~~~2~~~~~1-E~~~2~ie 
The course of pneumococcal pneumonia in CVF-treated rats was more 
severe than the infection in normal animals as described earlier (2), 
in short: the total body weight and rectal temperature decreased, 
the value of the latter to far below normal. The increase in weight 
of the left lobe of the lung was sevenfold. By 108 h the number of 
pneumococci cultured from the left lobe of the lung reached an average 
number of 3 x 10 10 pneumococci. Soon after initiation of the infection 
cultures of blood and pleural fluid were positive; by 108 h an average 
of 2 x 106 bacteria per milliliter of blood were cultured. In CVF-treated 
rats the clindamycin therapy of 2 mg/kg every 12 h was unsuccessful in 
eradicating the pneumococcal infection. After an initial decrease, 
total body weight remained constant at a subnormal level (Fig. 2A). 
Rectal temperature normalized (Fig. 2B). The weight of the left lobe 
of the lung doubled (Fig. 2C). By 132 h, an average of 6 x 107 
pneumococci were cultured from the left lobe of the lung (Fig. 2D). 
All cultures of blood and pleural fluid were sterile at 132 h (Fig. 2E 
and 2F). After injections of double doses of clindamycin, i.e. 4 mg/kg 
every 12 h starting at 36 h, the lungs were still not sterilized; an 
average of 8 x 105 pneumococci was still cultured from the left lobe 
of the lung at 132 h (Fig. 3D). An increase in clindamycin dosage of 
4 times was required for complete recovery of the CVF-treated rats 
(Fig. 4). The clindamycin dosage of 8 mg/kg every 12 h starting at 36 h, 
was successful in sterilizing the lungs of all CVF-treated rats 
at 132 h (Fig. 4D). 
E~~i~i11i~-i~ectiYeEi2~-!g_yitE2 
Three days after pneumococcal inoculation homogenates of infected lungs 
from normal and CVF-treated rats were tested for their capacity 
to inactivate penicillin. When penicillin was added to the lung 
55 
0 
* il ~ 
' 
21010 
l-:E ~lo8 -~10 ~ .e 
~ • :& 0 0 
~ 
'0 104 j 
20 E , 
A z D 
0 
0 36 84 hours 132 0 36 84 hours 132 
39 
-g 108 
0 
u :;; 
0 37 ~ 106 • , 
' ;; 
• 8. 0 104 E 0 
.! 35 ~ 0 
• 
102 
~ 
E 
B 
, 
E z 33 0 
0 36 84 hours 132 0 36 84 hours 132 
E 4 
e 
~ 
~ 
< 
.2 Culture of Pleural Fluid 
::;; 2 Pos. 1 0 0 
Neg. 4 5 5 
:E :. I" ~ 0 36 84 hours 132 ~ 0 c F 
0 36 84 hours 132 
Fig. I. Ac:tion of cZindamycin at 2 mg/kg body weight every 12 h starting 36 h after 
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viabZe pneumococci per miZZiZiter bZood. (F) CuZture of pZeuraZ j1uid. 
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viabLe pneumococci per miz:liliter blood. (F) Culture of pleural fluid. 
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homogenates to a final concentration of I ~g/ml, 60-70% was found 
immediately after mixing (0 h), and after 1~ and 6 hours incubation 
the concentration of penicillin was unchanged. When penicillin was 
added to the lung homogenates to a final concentration of 10 ~g/ml, 
80-90% was found immediately after mixing (0 h); samples tested 
after 1! and 6 hours incubation, yielded the expected concentration 
of penicillin. These experiments revealed that the amount of peni-
cillin added to the homogenates of infected lungs of normal and of 
CVF-treated rats did not decrease substantially within 6 hours of 
incubation at 37°C. It must be concluded that the slight decrease 
in penicillin concentration immediately after mixing, was due not 
to inactivation of the penicillin but probably to an initial binding 
of penicillin to the tissue homogenate. As a control, homogenates of 
healthy lungs were mixed with penicillin (final concentration 1 and 
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Fig. 5. Serum concentrations of elindamycin. Rats 
were injected intramuscularly with elindamyein 
doses of 2 mg/kg (---.! and 8 mg/kg (-J. Eaeh 
point represents the mean value of five rats 
(~standard deviation). 
10 ~g/ml) and assayed against penicillin standards in phosphate 
buffered saline, pH= 7.3 that were stored at 4°C. In these 
experiments 40-50% of the penicillin added to the lung homogenates 
was found immediately after mixing (0 h) and the same after 1~ and 
6 hours of incubation. Obviously penicillin had lost + 50% of its 
activity probably as a result of binding to the healthy lung tissue. 
Six hours of incubation at 37°C did not alter the amount of free 
penicillin in healthy lung homogenate. 
~~!~-~~!fbi2EfE_1~Y~1~ 
Intramuscular injections of 2 and of 8 mg/kg clindamycin gave peak 
concentrations in the serum of 0.25 ~g/ml and 1.2 ~g/ml respectively. 
Levels exceeding the MIC of pneumococci for clindamycin i.e. 
0.024 ~g/ml were present for about 6 and 12 h respectively (Fig. 5). 
Discussion 
Clinical experience has established the efficacy of clindamycin for 
treatment of mixed aerobic and anaerobic pulmonary infections. Several 
investigators studied the therapeutic effect of penicillin and clinda-
mycin on lungabcesses generally caused by anaerobic or mixed aerobic 
and anaerobic bacteria (1, 6, 8, 9, 12). Most of these studies revealed 
that there was no difference between the efficacy of these two 
antibiotics. Clinical experience with penicillin as well as with clinda-
mycin in the management of these infections has been good. Balachandar 
demonstrated the efficacy of clindamycin in children with pneumonia, 
whose throat cultures revealed Streptoeoec~ pneumoniae; the clinical 
response of these children to intramuscular clindamycin phosphate was 
excellent (4). 
In general it can be concluded from this and from other studies that 
clindamycin can be an effective drug in the treatment of severe infec-
tions, particularly in patients who are hypersensitive to penicillin, 
and in those whose infections are caused by organisms resistant to 
penicillin (4). 
In this study we investigated the efficacy of clindamycin treatment to 
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cure pneumococcal infection in normal rats and in rats with impaired 
phagocytosis of pneumococci. We compared these results to results found 
earlier describing the efficacy of penicillin (2, 3). Impairment of 
phagocytosis was accomplished by removing complement component C3 which 
is the principal component involved in the opsonization of pneumococci 
before specific antibodies develop. C3 depletion was accomplished by 
repeated injections of the rats with cobra venom factor (2). 
Although the antimicrobial sensitivity in vitro to both antibiotics was 
the same for the used pneumococcal strain, and although the antimicrobial 
activity in vivo of both drugs was the same in normal rats, the minimal 
effective dosage schedules of each antibiotic appears to be different 
in rats with impaired host defense mechanisms. The minimal effective 
dosage of clindamycin to cure experimental pneumonia in normal rats was 
2 mg/kg every 12 h started 36 h after the initiation of the infection; 
this was similar to the treatment schedule with penicillin (2). It was 
demonstrated that for both antibiotics, penicillin and clindamycin, 
this treatment schedule was not successful in CVF-treated rats which 
had impaired host defense to pneumococcal infection (2, present study). 
The therapeutic effect of the antimicrobial therapy could be restored 
by a 25-fold increase in the daily dose for penicillin (3) and by a 
4-fold increase for clindamycin (present study). 
That the increase in dosage required for treatment of the pr1eumococcal 
infection in CVF-treated rats was considerably greater for penicillin 
than for clindamycin, might be explained by inactivation of the peni-
cillin by inflammatory exudate at the site of infection. Recent 
literature reported probable enzymic inactivation of penicillin in 
inflammatory exudates; this agent which destroyes penicillin, was not 
derived from bacteria but apparently from host cells (5, 10, 11). Barnes 
et al. demonstrated that pus from a patient with an empyema due to a 
fully penicillin-sensitive hemolytic group B Streptoeocc~ inactivated 
the penicillin added in vitro. Various antibiotics were tested. No 
important inactivation of clindamycin in the presence of pus was seen 
(5). De Louvois et al. reported that four out of 22 specimens of 
human pus were able to inactivate penicillin (11). 
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The results of our penicillin inactivation experiments make it 
improbable that the loss of activity of penicillin in the GVF-treated 
rats was due to inactivation of the antibiotic by inflammatory exudate. 
Although the pulmonary lesions in the GVF-treated rats were very 
extensive compared to the lesions in normal rats, the homogenates of 
3 days'-infected lung tissue of these GVF-treated rats and normal rats 
did not inactivate added penicillin. Therefore, it is improbable that 
failure of penicillin treatment of pneumococcal pneumonia in 
GVF-treated rats is the result of inactivation of the penicillin at 
the site of the infection. 
In an attempt to explain the difference in efficacy of the two 
antimicrobial drugs, the clindamycin serum level was determined at 
different times after its administration and compared to penicillin 
levels (described earlier). These estimations showed that intramuscular 
injections of the same doses of penicillin and of clindamycin gave 
rise to completely different serum levels in the rat, both with 
regard to peak values and as to duration of adequate levels. Serum 
levels of antibiotics above the MIG for pneumococci were maintained 
for a much shorter period with penicillin than with clindamycin. 
After injection of the drugs in a dosage rate of 2 mg/kg the 
duration of the periods where the levels exceeded the MIG for pneu-
mococci were about 1~ hand 6 h for penicillin and clindamycin 
respectively (3, present study). Actually, serum levels constantly 
above or equal to the MIG of the pneumococcus to clindamycin were 
only found if a treatment schedule of 8 mg clindamycin per kg every 
12 h was applied. At the site of infection clindamycin might there-
fore be more effective than penicillin. The course of pneumococcal 
infection in GVF-treated rats was more severe than the infection in 
normal rats; the pneumonia spread more rapidly in the GVF-treated 
rats, and the pulmonary lesions were more extensive (2). Evidently a 
continuous high level of the antimicrobial drug in the tissue is an 
essential condition for curing the infection in the GVF-treated rats. 
From the present experimental study and from other studies described 
earlier (2, 3) two conclusions can be drawn: first, the loss of 
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activity of antibiotic treatment (penicillin or clindamycin) of pneu-
mococcal infection result's from selectively impaired phagocytosis in 
the infected host, and secondly the loss of phagocytic functions of 
granulocytes can be compensated by an improved antibiotic treatment 
schedule. In the latter case the choice of antimicrobial agent depends 
not only on the antimicrobial susceptibility of the infecting 
organism, but also on the pharmacological properties of the 
antimicrobial drug. In pneumococcal pneumonia with extensive 
pulmonary lesions due to impaired phagocytosis, it is absolutely 
essential to apply antibiotic treatment schedules that give rise to 
prolonged inhibitory antibiotic serum levels in the interval between two 
successive injections. 
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Chapter 4 
EFFECT OF SPLENECTOMY UPON THE COURSE OF EXPERIMENTAL PNEUMOCOCCAL 
BACTEREMIA IN RATS AND THE EFFICACY OF PENICILLIN THERAPY* 
Irma A.J.M. Bakker-Woudenberg, P. de Bos, A.L.E.M. van Gerwen, 
W.B. van Leeuwen, and M.F. Michel 
Department of Clinical Microbiology and Antimicrobial Therapy~ 
Erasmus University Rotterdam~ The NetherlandS 
Evidence is presented about increased susceptibility to pneumococcal 
infection after splenectomy in young rats and after splenectomy in 
adult rats with low serum opsonic levels. The penicillin therapy 
which prevented mortality in normal intravenously infected rats, had 
lost its activity in splenectomized young rats and splenectomized 
adult rats with low serum opsonic levels. By markedly increasing the 
dose of penicillin the efficacy of the antibiotic was restored in 
those animals. 
Introduction 
For many years it has been recognized that patients with anatomic or 
functional asplenia are subject to episodes of fulminating, often 
lethal bacterial infections, frequently caused by the pneumococcus. The 
occurrence of such infections in patients with hyposplenism (9, 16) is 
documented by clinical studies in patients functionally asplenic by 
Sickle cell disease (19, 20) and in patients splenectomized for trauma 
(2, 13, 18) or Hodgkin's disease (6, 8, 10). It has become clear that 
the risk of developing postsplenectomy sepsis is related to a number 
of variables. One factor is the age of the patient at the time of 
splenectomy. Adults seem to be at less risk of postsplenectomy sepsis 
* will be published in J. Infection. 
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than children. The reason for performing splenectomy is also an 
important factor. Some authors suggest that splenectomy per se carries 
some increased risk of acquiring overwhelming infections, even in 
otherwise normal individuals (2, 13, 18). Other authors have reported 
that the relative risk of postsplenectomy infection appears to be a 
function of the underlying disease. The risk is high in patients who 
received chemotherapy for haematologic malignancies such as Hodgkin's 
disease (6, 8, 10, 26, 27). The primary disease itself is associated 
with increased susceptibility to infection which in turn predisposes 
the patient to overwhelming and frequently fatal infection when the 
spleen is removed. 
In this animal study we investigated the effect of splenectomy upon 
the course of pneumococcal bacteremia, and whether removal of the 
spleen influenced the amount of penicillin required for surviving the 
infection. Experimental conditions similar to clinical situations 
were chosen. Variables of age and opsonic capacity of the serum were 
introduced by using young and adult rats and by treating adult rats 
with cobra venom factor. 
Materials and Methods 
~~!~1~ 
Female R-strain albino rats (random bred; specific pathogen free; bred 
in the Laboratory Animals Center of the Erasmus University Rotterdam) 
were used in all experiments. Adults rats 14-18 weeks old, weight 
180 to 210 g, young rats 3-4 weeks old, weight 50 to 80 g. 
~~££~!!~ 
A Streptococcus pneumoniae type III strain (isolated from a clinical 
case) was used in all experiments. The minimal inhibitory concentra-
tion (MIC) for penicillin was 0.024 ~g/ml (tube dilution test). 
The virulence of the bacteria was maintained by passage in rats every 
4 months and storage at -70°C in Todd-Hewitt broth (Oxoid) with 
10% glycerol (Merck). 
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~E1~~~SE~~ 
Adult rats or young rats were splenectomized or sham operated. 
Splenectomies and sham operations were carried out under anesthesia 
with Hypnorm (Duphar) and pentobarbital (adult animals) or ether 
anesthesia (young animals). Splenectomy was performed through a 
small lateral left flank incision. The abdominal wall was closed 
with silk sutures; the skin was closed with skin clips (adult animals) 
or silk (young animals). 
EE~~f~~~f-~iEg_E££E~-~~~£~-~~SE£E 
The venom of the Cobra (Naja naja siamensis) was purified and kindly 
supplied by I.J.C. Wilschut (29). One unit of cobra venom factor (CVF) 
amounted to 10 ~g of the purified material. Rats were injected intra-
peritoneally 14 times with CVF (two doses 0.14 units/kg body weight, 
twelve doses 0.07 units/kg body weight). The first dose was 
administered 12 hours before pneumococcal inoculation, followed by 
five doses every 8 h and eight doses every 12 h. To determine 
complement depletion in vivo rats were bled at several times during 
CVF treatment by orbital puncture. Sera were tested by an assay of 
complement hemolytic activity as described earlier (1). The data 
derived from this assay were presented as SO% complement hemolysis 
units per milliliter, corresponding to the reciprocal value of the 
serum dilution that gave 50% hemolysis. Earlier experiments (1 and 
unpublished) revealed a correlation between the level of circulating 
C3 and the whole complement hemolytic activity in serum after CVF 
treatment. 
!~_YiE!£_EgeE£EY!£~i~ 
Experiments of in vitro phagocytosis of pneumococci by PMN were 
performed as described earlier (1). In short: pneumococci were 
preincubated in rat serum and added to a suspension of leukocytes 
obtained from rat peritoneal washings. After 30 min phagocytosis was 
stopped, the cells were washed and were examined under a microscope 
in Gramrstained smears. 
69 
~g!!eY~g~~~-~g~s~1e!~2g 
Adult rats and young rats were 
suspensions of 2 x 108 and 0.7 
challenged by inoculation with 0.5 ml 
8 s . x 10 . pneumon~ae type III cells, 
respectively, into the tail vein. Mortality determinations were 
terminated one week after inoculation. For clearance studies blood 
samples (0.2 ml) were obtained by orbital puncture at 5, 15, 50, 100, 
.ISO min after challenge and these were quantitated for viable 
bacteria. 
eg!!~~I~~~e1_£E~e!~~g£_e!E~E_ig£EeY~g~~~-Eg~~~s~ss~1-1g~s~1eEi£g 
The sodium salt of penicillin G in aqueous solution was used. 
Individual doses of penicillin amounted to 0. 1, 0.5, I, 2, 5, 10, 15, 
20, 25, 30, 35, 45, 55 mg/kg body weight. Penicillin injections were 
given every 12 h intramuscularly into the thigh muscles of the rear 
legs. Fourteen injections were given, the first 2 h after intravenous 
inoculation of pneumococci. 
~~E~_eg£~£i£E~s_1~Y~!~ 
Serum antibiotic levels were determined after intramuscular 
injections of penicillin amounting to 0.5, 2, IO or 55 mg/kg body 
weight. Blood specimens for antibiotic assay were obtained by orbital 
puncture under light ether anesthesia. From each rat blood was 
collected at four different times after intramuscular injection of the 
antibiotic. 
eg!~£!£!!s_e~~eY 
Penicillin levels were estimated by a standard agar diffusion method 
(3) with some modifications. For determinations of serum levels below 
0.5 ~g/ml penicillin, sensitivity test agar* and a Bacillus 
stearother,mophiZus strain as the indicator organism were used, and 
incubations were performed at 56°C (sensitivity of this assay system 
was 0.06 ~g/ml penicillin). For determination of serum levels above 
0.5 ~g/ml penicillin, Oxoid diagnostic sensitivity test agar and a 
Staphylococcus aureus strain (ATCC 9144, strain Oxford) as the 
*0.5% tryptone, 0.25% yeast extract, 0.1% glucose, 1.5% agar (Difco) 
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indicator organism were used, and incubations were performed at 37°C 
(sensitivity of this assay system was 0.25 ~g/ml penicillin). Tests 
were performed with 50 ~1 of rats serum per test. 
Results 
The effect of splenectomy upon the course of infection and the 
efficacy of antimicrobial therapy was studied in a model of pneumo-
coccal bacteremia. Several groups of rats were used. Variables such 
as the age at the time of splenectomy, interval since splenectomy 
and increased susceptibility to pneumococcal infection due to 
impaired phagocytosis, were introduced in this study (Table I). In 
all experiments sham-operated rats were compared with age-matched 
normal control rats. We found no difference in the course of pneumo-
coccal bacteremia in shamroperated rats and unoperated rats, not even 
when the animals were only 3 weeks old. Shamroperated rats will 
therefore not be mentioned further. 
Table I. 
A~e at time of Ase at time of 
Animals SE 1 enectcmz Pneumococca 1 
infection 
A normal adu 1 t rats 18 weeks 
B norma 1 adult rats 17 weeks 18 weeks 
c norma 1 adu 1 t rats 14 weeks 18 weeks 
D normal adult rats 3 weeks 18 weeks 
E CVF-treated adult rats 18 weeks 
F CVF -treated adult rats 17 weeks 18 weeks 
G CVF-treated adult rats 14 weeks 18 weeks 
H CVF-treated adult rats 3 weeks 18 weeks 
young rats 4 weeks 
J young rats 3 weeks 4 weeks 
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~ff~£!~-~f-E££E~-Y~~~~-£~~!£E 
By means of multiple injections of CVF (two injections 0.14 units/kg, 
twelve injections 0.07 units/kg) whole complement hemolytic activity 
in serum was kept at ~ 25% of the normal values starting from 12 h 
after the first CVF injection. Compared to normal rat serum (100%) 
the opsonic activity of the serum of CVF-treated rats was reduced to 
62%, as evidenced by an impaired phagocytosis of pneumococci in vitro 
by PMN. 
deaths/ deaths/ deaths/ 
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no rats( 1) no rats (2) no rats( 3 ) 
A 0/10 0/10 3/10 
B 1/10 1/10 2/10 
c 2/10 3/10 3/10 
D 0/10 0/10 2/10 
E 1/10 5/10 6/10 
F 7/10 10/10 10/10 
G 9/10 10/10 10/10 
H 10/10 10/10 10/10 
0/10 1/10 2/10 
J 1 /1 0 7/10 8/10 
1 ) 12 hours after inoculation 
2) 24 hours after inoculation 
3) week after inoculation 
Table II. Mortality in rats after i.v. inoculation of adult 
rats and young rats mth respeetively 2 x 108 and 0.? x 108 
Streptococcus pneumoniae. type III. (A) Normal adult rats~ 
(B) nonnal adult rats inoeuZated 1 week postspleneetomy, 
(C) nonnal adult rats inoeulated 4 weeks postspleneetomy, 
(D) normal adult rats spleneetomized at young age and 
inoeuZated 15 weeks postspleneetomy, (E) CVF-treated adult 
rats, (F) CVF-treated adult rats inoeulated 1 week post-
spleneetomy, (G) CVF-treated adult rats inoeuZated 4 weeks 
postspleneetomy, (H) CVF-treated adult rats spleneetomized 
at young age and inoc~Zated 15 weeks postspZenectomy~ (I) 
young .rats:~ (J) young rats inoau.Zated 1 week postspZenectomy. 
~~E~Ei~~~Ee!-E~~~~£~££~!_£e££~E~~i~-i~~E!~~~££~~~~~-E~!~ 
Groups of 10 rats were inoculated intravenously. Parameters for the 
severity of pneumococcal bacteremia were: mortality after 12 h, 24 h 
and 1 week (Table II), and clearance of pneumococci from the blood 
stream (Fig. I through 3). 
After intravenous inoculation of 2 x 108 pneumococci none of the 
adult rats died within the first 24 h; after 1 week the mortality was 
30%. The mortality rate in rats splenectomized week, 4 weeks or 
15 weeks prior to infection, was slightly higher but not significantly 
(Fisher test P > 0.05). CVF-treated normal adult rats had an increased 
mortality within the first 24 h (Fisher test P= 0.03). All 
splenectomized CVF-treated rats died within the first 24 h; compared 
with the mortality rate of normal CVF-treated rats, mortality rates 
were significantly higher in these rats (Fisher test P= 0.03). The 
mortality rate in splenectomized young rats inoculated with 0.7 x 108 
pneumococci was significantly higher than the mortality rate in normal 
young rats (Fisher test P= 0.02). 
Clearance of pneumococci was determined at 5, 15, 50, 100, 150 minutes 
after intravenous injection of adult rats and young rats with 2 x 108 
and 0.7 x 108 pneumococci, respectively. The clearance curves are 
shown in Fig. I, 2, and 3. There was a rapid clearance of viable pneu-
mococci in normal adult animals (Fig. 1). In splenectomized adult 
animals the clearance rate was slightly different compared to controls 
(Fig. I). Within the first 100 minutes after the inoculation 85% of the 
pneumococci were cleared. CVF-treated animals cleared the pneumococci 
at a somewhat slower rate (Fig. 2). In contrast splenectomized 
CVF-treated animals were not able to clear pneumococci from the blood 
stream (Fig. 2). After a decrease during the first hour the number of 
bacteria increased again, and 150 minutes after the inoculation the 
number of viable bacteria in the blood was significantly higher than 
the number found in the controls (Wilcoxon rank-sum test P < 0.01). 
The clearance curve of the young animals (Fig. 3) compared well to the 
clearance curve in adult animals (Fig. 1) although within the first 
hour clearance seemed to be less in young animals. The clearance curve 
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Fig. I. 
Fig. 2. 
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Fig. I. Viable bacterial counts in blood after i.v. inoc~lation of 
8 2 x 10 Streptococcus pneumoniae type III. Each point Pepresents the 
mean value of four rats (7:_ etandal'd de<Jiation). (A) NormaZ adult r•ats 
{.--), (B) normal adult rats inoculated 1 week postsplenectomy !---~, 
(C) normal adult rats inoculated 4 weeks postsplenectomy F--~, (D) 
normal adult rats splenectomized at young age and inoculated 15 weeks 
postsp lenectomy (,..- -). 
Fig. 2. ViabZe bacterial counts in blood after i.v. inoculation of 
2 x 108 Streptococcus pneumoniae type III. Each point repr-es-ents the 
mean value of four· rats (:':_ standard de"iation). (E) CVF-treated adult 
rats (---), (F) (CVF-treated adult rats inoculated 1 week postsplenec-
tomy ~--i, (G) CVF-treated adult rats inoculated 4 weeks postsplenec-
tomy {-.......;, (H) CVF-treated adult rats splenectomized at young age and 
inoculated 15 weeks postsplenectomy {,-.....;. 
Fig. 3. Viable bacterial counts in blood after i.v. inoc~Zation of 
8 0.7 x 10 Streptococcus pneumoniae type III. Each point represents the 
mean value of four rats (:':_ sta:ndca-d deviation). (I) Young rats ?--J, 
(J) young rats 1 week postsplenectomy {.--1. 
75 
of splenectomized young animals showed an initial decrease of pneumo-
cocci followed by bacterial multiplication (Fig. 3). 
e~~b~SE~£be1_~E~e~~~E-~!-~!E~Ei~~g~e1_Ene~s~ss~!_£~s!~E~~e_i~ 
~E1~n~£££_miz~~-Ee5~ 
Groups of ten rats (adult rats or young rats) were inoculated intra-
venously with pneumococci (2 x 108 or 0.7 x 108 respectively). After 
penicillin treatment at a dosage rate of 0.5 mg/kg/12 h starting 2 h 
after inoculation, normal adult rats did not die within the first 
week after inoculation. In CVF-treated rats a 20-fold increase in 
dosage (10 mg/kg/12 h) was required for survival, and in splenectomized 
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Fig. 4. Serum concentrations of penieiZZin. Adult rats were injected 
intramuscularly with penicillin dOses of 0.5 mg/kg (---), 10 mg/kg 
(----) a:nd 55 mg/kg (- -). Young rats were injected intramuscularly 
with penicillin dOses of 0.5 mg/kg (-·-·-) a:nd 2 mg/kg (.- ...... ). Each 
point represents the mean value of five rats (+ standard deviation). 
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CVF-treated animals the minimal effective penicillin dose had to be 
increased even further (55 mg/kg/12 h). Young animals were cured by 
the same dosage of penicillin (0.5 mg/kg/12 h) as was used for adult 
animals. After splenectomy of the young rats the ~nimal effective 
penicillin dosage had to be increased to 2 mg/kg/12 h. 
~~E_~~g!i£1£Ei~-1~Y~1~ 
Intramuscular injections of adult rats with penicillin doses of 
0.5, 10, and 55 mg/kg and of young rats with penicillin doses of 
0.5 and 2 mg/kg, gave rise to penicillin levels which differed in peak 
heights and duration of penicillin concentrations equal to or above 
the minimal inhibitory concentration (MIC) for the pneumococcus 
(0.024 ~g/ml) (Fig. 4). Administration of 0.5, 10 and 55 mg/kg to adult 
rats gave peak concentrations of 0.6, 12 and 62 ~g/ml, respectively; 
estimated minimal effective serum concentrations of 0,024 ~g of peni-
cillin per ml or more were present for about 60, 130 and 250 ~n, 
respectively. Ad~nistration of 0.5 and 2 mg/kg to young animals 
gave peak concentrations of 1,1 and 2,9 ~g/ml, respectively; estimated 
minimal effective serum concentrations of 0.024 ~g of penicillin per 
ml or more were present for about 60 and 70 min, respectively. 
Discussion 
The effects of splenectomy upon the course of infection and the 
efficacy of antimicrobial therapy were studied in a rat model of 
pneumococcal bacteremia. Variables such as the age at the time of 
splenectomy, length of time since splenectomy and increased 
susceptibility to pneumococcal infection due to impaired phagocytosis, 
were introduced in this study. Phagocytosis of encapsulated pneumo-
cocci occur after opsonization of the bacteria (24), and impairment 
of phagocytosis was accomplished by removing the opsonins. Complement 
component C3 is the principal component involved in the opsonization 
process (30), and phagocytosis of pneumococci was therefore impaired 
by reducing the amount of C3. Reduction of C3 was accomplished by 
77 
repeated injections of the rats with cobra venom factor (CVF). It is 
known that this factor causes depletion of plasma C3 in several species 
(1, 15, 21). The present study showed that the CVF-treated rats had 
decreased levels of plasma C3 in their sera. The opsonic capacity of 
these sera was impaired, as measured by in vitro phagocytosis of 
pneumococci by PMN. 
Our experiments showed that the course of infection after intravenous 
inoculation of pneumococci was influenced by removal of the spleen in 
young rats and in CVF-treated adult rats. In these two groups of 
animals asple~ia gave rise to increased mortality, which appeared to 
be correlated with inability to remove pneumococci circulating in the 
blood. Splenic phagocytosis was of critical importance in the face of 
a quantitative deficiency in opsonins. 
Other experimental studies also showed an increased mortality in 
splenectomized rats and mice after intravenous pneumococcal challenge 
(17, 25, 28). Coil demonstrated an increase in mortality after 
splenectomy in mice after pneumococcal infection via an aerosolized 
atmosphere (7). Our experimental data differ from the findings by 
59 Biggar who demonstrated a delay in clearance of Fe-labelled pneumo-
cocci in adult rats (13 weeks old) if splenectomy preceded infection 
by five days; however sera from these rats, tested five days after 
splenectomy, had no demonstrable deficiency in capacity to promote 
in vitro phagocytosis of pneumcocci by PMN (4, 5). The discrepancies 
between these results may be due to the use of organisms with varying 
virulence, the use of different species and the use of animal strains 
with different susceptibili'ties. Selection of host and parasite is 
criticaL 
In our experiments inability to clear pneumococci after intravenous 
infection as a result of splenectomy was only demonstrated in young rats 
and in CVF-treated adult rats. In normal adult animals the opsonic 
capacity of the serum is sufficient for adequate phagocytosis of pneumo-
cocci. When the C3 level was reduced by treatment with CVF, pneumococcal 
opsonic capacity of the serum was diminished as evidenced by impaired 
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phagocytosis of the pneumococci in vitro by PMN. This resulted in a 
delay in pneumococcal clearance and increased mortality. Pneumococcal 
clearance studies in guinea pigs treated with CVF also demonstrated 
that although a clearance was initiated, bacteria started to multiply 
again, a condition that led to the animals' death (12). 
Some clinical investigations showed that increased susceptibility for 
pneumococcal infections was found in splenectomized individuals with 
an abnormality of the alternate complement pathway and in patients 
with Sickle cell disease (14, 23). The absence of the spleen permits 
the organisms to circulate and therefore multiply for a longer time, 
and, as seen in the clearance curves, this may lead in a short time to 
a dangerously high blood stream concentration of bacteria. 
In splenectomized animals with increased mortality to intravenous 
pneumococcal infection, the efficacy of penicillin therapy was tested. 
Penicillin in a dosage rate of 0.5 mg/kg/12 h starting 2 h after 
inoculation of pneumococci prevented mortality of normal adult rats 
and young rats. Inhibitory serum concentrations of 0.024 ~g/ml or 
more of penicillin were present for 65-70 min in both the adult and 
the young rats. To cure CVF-treated rats, splenectomized four weeks 
before infection, or young rats, splenectomized one week before 
infection, the penicillin dosage had to be increased (0.5 to 
55 mg/kg/12 h or 0.5 to 2 mg/kg/12 h respectively). These observations 
suggest a correlation between a need for an increased penicillin 
dosage and an increased bacteria count in the blood. This supports 
previous studies of Perry a.o. suggesting that the lethal outcome of 
pneumococcal infection was related to the total mass of multiplying 
pneumococci (22). Our findings correspond to some clinical reports 
that hyposplenic patients did not respond well to penicillin therapy 
(11, 13). Prompt penicillin treatment in high doses of suspected 
postsplenectomy pneumococcal infection is desirable. 
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Chapter 5 
EFFICACY OF ANTIMICROBIAl THERAPY IN EXPERIMENTAl LISTERIOSIS 
IN MICE: AMFICILLIN TREATMENT SCHEDULES IN MICE WITH IMPAIRED 
T-CELL-MEDIATED IMMUNE RESPONSE* 
Irma A.J.M. Bakker-Woudenberg, P. de Bos, W.B. van Leeuwen, and 
M.F. Michel 
Department of Clinical Microbiology a:nd Antimicrobial Therapy, 
Erasmus University Rotterdam, The Netherlands 
The importance of intact host defense mechanisms for successful 
antimicrobial therapy was investigated in an animal model. Recovery 
from experimental infections caused by Listeria monocytogenes as 
a result of ampicillin therapy was studied in normal mice and in 
congenitally athymic (nude) mice. Nude mice were used for these 
experiments because antimicrobial resistance to Listeria monocytogenes 
depends on the development of cellular immunity, induced specifically 
by a T-cell-mediated reaction. These experimental studies revealed 
that the ampicillin therapy that cured normal mice infected with 
Listeria monocytogenes, had lost its activity in mice with impaired 
cell-mediated immunity. Lack of cellular immunity can not be 
compensated by intensification of the ampicillin treatment schedule, 
in terms of higher dose and/or shorter dosage interval and/or 
prolonged treatment. 
Introduction 
Listeria monocytogenes is an uncommon cause of septicemia and 
meningitis in healthy adults but can produce severe infections in 
neonates and in patients with compromised defense mechanisms. 
*A shortened version will be published in Antimicrob. Agents Chemother. 
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Patients with underlying malignancies such as lymphoma's and 
leukemia's, and immunosuppressed patients such as renal transplant 
recipients receiving azathioprine and corticosteroids have shown 
considerable susceptibility to infections due to opportunistic 
pathogens such as Listeria monocytogenes (1, 10, 13, 19, 22, 25, 29). 
The susceptibility of patients with malignant diseases of lymphatic 
cells to these infections may be ascribed to defects in their 
cell-mediated immune mechanisms (6, 11). Such defects may be inherent 
to the underlying disease, but the inhibition of cell-mediated immune 
response by immunosuppressive drugs must also be weighed. 
Data from several studies suggest that ampicillin is the drug of 
choice for the treatment of infections due to Listeria monocytogenes 
(12, 17, 27). However, despite the organism's usual sensitivity, 
therapeutic failures have occurred in patients with impaired host 
defense mechanisms (14, 25, 26, 32). Reasons for the failure of 
apparently appropriate antibiotic therapy are discussed by Watson 
et al. (32) and the synergistic effect of certain antibiotic 
combinations in vitro against Listeria was demonstrated by Moellering 
(23) and Esp~ze (9). 
In the present study we investigated the role of T-cell-mediated 
immunity in relation to ampicillin therapy of listeric infection in 
normal mice and mice with impaired T-cell-mediated immunity. 
Materials and Methods 
~ni~l:~ 
Female BJOLP nude mice homozygote for the mutation 'nude' (nu/nu) and 
their age-matched immunologically normal controls heterozygote for 
the nude gene (nu/+) (specific pathogen free; 10-12 weeks old; bred 
in the Laboratory Animals Center TNO Zeist, the Netherlands) were 
used in all experiments. 
2~S.!:~!i~ 
A Listeria monoeytogenes type 4b strain (isolated from a clinical 
easel was used in all experiments. The minimal inhibitory concentration 
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for ampicillin was 0.16 ~g/ml (tube dilution test). The virulence of 
the bacteria was maintained by passage into the yolk sac of 10-day old 
chicken embryos. After death of the embryo (after 3-5 days) the yolk 
sac material was inoculated on blood agar, and incubated for 16 h 
at 37°C. Beef broth was inoculated with these Listeria and after 
incubation, for 16 h at 37°C, this stock culture was stored at -70°C 
in small aliquots. A stock culture was thawed and used to seed a fresh 
culture for each animal inoculation. The bacterial culture was 
incubated for 16 h at 37°C. After incubation the stationary phase 
culture was kept at 4°C. The culture contained 2 x 109 viable 
organisms per ml (ranges 1.8-2.2 x 109). To prepare the inocula, the 
16 h culture was appropriately diluted with physiological saline. To 
ensure identical inocula, for each experiment the number of viable 
organisms was determined before and just after animal inoculation. 
~~~!i~~~£e1_igfe££i2g 
Mice (10-12 weeks old) were infected by injection of 0.5 ml of a 
suspension of Listeria monoGytogenes cells into the tail vein. 
4 4 5 Inocula amounted to 5 x 10 (ranges 4.5-5.5 x 10 ), 10 (ranges 
0.9-1.1 x 105) and 5 x 105 (ranges 4.5-5.5. x 105 ) bacteria. The 
severity of the infection was indicated by the number of viable 
Listeria present in the spleen, liver and blood. At different 
intervals following the intravenous inoculation and at least 5 h after 
injection of ampicillin, the mice were sacrificed and the spleen and 
liver were removed. Individual organs were homogenized separately in 
20 ml physiological saline (VirTis homogenizer, 30 sec. 10.000 rpm). 
The tissue homogenates were diluted serially tO-fold with saline, and 
0.2 ml of each dilution was spread on blood agar base; finally the 
total homogenate was tested for viable bacteria by the pour-plate 
method. After dissection and macroscopic examination no thymus could 
be found in nude mice. 
~g£i~icr~£i21_£!~~~~g£ 
The sodium salt of ampicillin (Beecham Farma B.V., The Netherlands) 
was administered in aqueous solutions. Individual doses of 
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ampicillin amounted to 5, 10, 25 and 50 mg/mouse. Ampicillin 
injections were given either every 12 or every 8 h subcutaneously. 
Eight, twelve, sixteen or thirty-two injections were given, the first 
dose 36 h after the intravenous bacterial inoculation. 
~~!i£i£Ei£_~~~~r 
Bloodspecimens for antibiotic assay were obtained by orbital puncture 
under light anesthesia with ether. From each mouse blood was collected 
at three different times after ampicillin injection. Ampicillin levels 
were estimated by a standard large-plate agar diffusion technique 
with Oxoid diagnostic sensitivity test agar and a Staphylococcus 
aureus strain (ATCC 9144 strain Oxford) as the indicator organism (2). 
Sensitivity of the assay system was 0.25 ~g/ml ampicillin. The 
coefficient of variation (CV) of the antibiotic determination was 
estimated for solutions containing concentrations within the range 
0.5-16 ~g/ml ampicillin. The CV of 12 determinations was 1-3%. 
Antibiotic assay were performed with 50 ~1 of mouse serum per test. 
Results 
The course of infection is indicated by the number of viable Listeria 
in the spleen and liver, presented in figures. 
1i~E~Ei£_i~f~SEf2~-i~-~E!~~E~~-~i£~ 
Figure 1 summarizes the results of Listeria spleen and liver counts 
in normal (nu/+) mice after intravenous inoculation of 5 x 104 , 105 
and 5 x 105 Listeria monocytogenes cells respectively. The course of 
infection depended on the number of bacteria injected. After inoculation 
of 5 x 105 Listeria all mice died within 48-72 h. Blood cultures were 
positive. After 36 h the average number of bacteria per milliliter blood 
was 380. Listeria multiplied rapidly in the tissues. At 36 h average 
numbers of 3 x 107 and 107 bacteria were cultured from spleens and 
livers respectively. Inoculation of normal mice with 105 Listeria 
resulted in a progressive increase in bacterial populations of the 
spleen and liver followed by a decrease in number of organisms between 
the third and the fifth day. The blood was sterile. Two mice out of 
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Fig. 1. Growth curves of Listeria monocytogenes in spleens and livers 
of normal (nul+) mice after intravenous inoc:ulation of 5 x 105 bacteria 
( ... ), 105 bacteria(-) and 5 x 104 bacteria(---). Each point 
represents the mean and ranges of five mice (linear scale). 
T mice died iha>ing the experiment. 
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Fig. 3. Growth aurves of Listeria monocytogenes in spleens and livers 
of nude (nu/nu) mice after intravenous inoculation of 5 x 105 bacteria 
( ... ), 105 bacteria (-} a:nd 5 x 104 bacteria (---). Each point 
represents the mean and ranges of five mice (linear seale). 
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55 mice died on the fourth and the fifth day respectively. The 
remaining animals recovered, and by day 16 spleens and livers were 
sterile. The spleens were now enlarged and there were signs of 
splenic necrosis. After inoculation of 5 x 104 Listeria all normal 
mice recovered quickly. The blood was sterile all the time. After 
10 days no bacteria could be cultured from the spleen and the liver. 
The course of listeric infection in nude mice did not depend on the 
size of the inocula investigated (Fig. 3). The nude mice inoculated with 
5 5 4 5 x 10 , 10 or 5 x 10 Listeria monoeytogenes did not recover from 
the infection, but they did not die. From the start of the infection 
the spleens were enlarged, no lesions or signs of splenic necrosis were 
seen. Indepeudantly of the number of injected bacteria, average numbers 
of 9.104 and 4.104 bacteria were cultured from spleens and livers 
respectively. Of the 45 nude mice infected with 5 x 105 Listeria only 
one mouse had bacteria in the blood on day six after inoculation: 
819 bacteria per milliliter blood was counted. The blood of all nude 
mice infected with 105 or 5 x 104 Listeria was sterile. 
The efficacy of ampicillin therapy was studied in normal mice and nude 
mice infected with 5 x 105 or 105 Listeria. 
~£i~i11ig_E~~!~EY_£f_g£~1-~g~L~l-~is~-~~-~~~~-~g~Lg~l-~~~-~fE~! 
in£~~1eEi£g_£f_2_~_lo5_f~-~£~~U~£ee~~ 
Eight injections of 5 mg ampicillin per mouse every 12 h, starting 36 h 
after initiation of the infection, could sterilize spleen, liver and 
blood of all normal mice within 14 days after bacterial inoculation 
(Fig. 2). This ampicillin treatment was unable to cure nude mice 
infected with the same number of Listeria (Fig. 4). Spleens and livers 
of ampicillin-treated mice contained the same numbers of bacteria as 
untreated mice. In an attempt to cure the nude mice with listeric 
infection, the ampicillin treatment was intensified by markedly 
increasing the daily dose of ampicillin (10, 25, 50 mg versus 5 mg) 
and/or the frequency of injections (from 12 h to 8 h) and/or the 
number of injections (32 versus 8 injections). Figures 5 through 7 
show the results of these experiments. None of these intensified 
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Fig. 2. Growth curves of Listeria monocytogenes in spleens and livers 
after intravenous inocuZation of 5 x 105 baeteria into normaZ !nul+! 
miee whieh reeeived ampieiZZin therapy 8 injeetions of 5 mg/mouse 
every 12 h starting at 36 h (-·-) and untreated eontroZs (---). Eaeh 
point represents the mean and ranges of five mice (Z.inear scale). 
T miee died during the experiment. 
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Fig. 4. Growth curves of Listeria monocytogenes in spleens and Z.ivers 
after intravenous inoculation of 5 x 105 bacteria into nude (nu/nu) 
mice which received ampiciZ.Zin therapy 8 injections of 5 mg/mouse 
every 12 h starting at 36 h (-·-) and untreated eontroZs (-). 
Eaeh point revresents ·the mean and ranges of five miee (Zinear seaZe). 
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Fig. 5. Growth curves of Listeria monocytogenes in sp~ens and livers 
after intravenous inoeulation of 5 x 105 baeteria into nude (nu/nu) 
miee which received ampicillin therapy 
8 injections of 10 mg/mouee every 12 h starting at 36 h ( -·-), 
8 injections of 25 mg/mouse every 12 h starting at 36 h (---), 
8 injections of 50 mg/mouse evex>y 12 h starting at 36 h ( ... ) , 
and untreated controls (-). Eaeh point represents the mean and 
ranges of fi~e mice (linear seale). 
0 
1 
! 
' I 
' 
' I I ' ' 
' 
' I 
Liver 
I 
I 
/ 
' I 
) 
I I 
I I 
o,L----~~-----+10---------L---230-- oL_--~~--'~~--~-~---~--~-o 10 20 
Time oftcr infection (dey~) 
Fig. 6. Growth curves of Listeria monocytogenes in sp~ens and livers 
after intravenous inoculation of 5 x 105 bacteria into nude (nu/nu) 
miee whieh reeeived ampieiZZin therapy 12 injeetions of 25 mg/mouse 
evex>y 8 h starting at 36 h (---) and untreated eontroZs (---). Eaeh 
point represents the mean and r>anges of five rrriee (linear seale). 
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Fig. 7. Growth eurves of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 5 x 105 bacteria into nude (nu/nu) 
mice which received ampicillin therapy 
16 injections of 5 mg/mouse every 12 h starting at 36 h (-·-), 
16 injections of 25 mg/mouse every 12 h starting at 36 h (---), 
32 injections of 25 mg/mouse every 12 h starting at 36 h ( •.. )3 
and untreated controls (---). Each point represents the mean and 
ranges of five mice (linear scale). 
treatment schedules were successful. After ampicillin treatment with 
increased dosages (Fig. 5) the number of bacteria especially those 
cultured from the liver decreased initially, but increased again as 
soon as ampicillin therapy was terminated. Six mice out of 105 treated 
with 8 injections of respectively 10 mg, 25 mg and 50 mg ampicillin 
every 12 h died within 14 days, probably as a result of the high ampi-
cillin dosages. Ampicillin treatment with an increased frequency and 
number of injections in combination with an increased daily dose (12 
injections of 25 mg/mouse every 8 h), apparently sterilized spleens 
and livers of most animals (Fig. 6). At day ten the numbers of bacteria 
cultured from spleen and liver of ampicillin treated mice was 
significantly lower than in untreated controls (Wilcoxon rank-sum 
test, P= 0.008). However, recovery was not complete. Three mice out of 
30 died within 20 days after inoculation. The numbers of bacteria 
cultured from spleen and liver at day 21 increased again to 
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pretreatment levels. After ampicillin treatment with an increased 
number of injections (16 versus 8 injections) in combination with an 
increased dose (25 versus 5 mg)., the numbers of bacteria cultured from 
spleens and livers initially decreased, but returned to the pretreatment 
level ten days after the termination of the therapy (Fig. 7). Treatment 
with 32 injections of 25 mg ampicillin per mouse every 12 h seemed to 
be successful (Fig. 7). One day after the last ampicillin injection 
no bacteria could be cultured from spleens and livers of nude mice. 
However, although the numbers of bacteria cultured from spleen and 
liver were significantly lower compared to untreated controls (Wilcoxon 
rank-sum test, P= 0.008) five days after the last ampicillin injection, 
Listeria could again be found in spleens and livers of all mice. The 
bacteria isolated from these organs were found to retain their ampi-
cillin sensitivity. 
~Ei£i11i~Eh~!~Qy_g£_gg~~!_i£~L!l_~i£~-~~-B~~~-iB~L~~l-~£~_e!~~E 
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Eight injections of 5 mg ampicillin per mouse every 12 h starting 36 h 
after bacterial inoculation, could sterilize spleen and liver of all 
normal mice within six days after initiation of the infection (Fig. 8). 
This ampicillin treatment was unable to cure nude mice infected with 
105 Listeria (Fig. 9). After an initial decrease, the number of 
bacteria present in spleens and livers increased again to pretreat-
ment levels. In an attempt to cure the nude mice with listeric 
infection the ampicillin treatment was intensified by markedly 
increasing the daily dose of ampicillin (25 versus 5 mg) and/or the 
frequency of injections (from 12 h to 8 h) and/or the number of 
injections (32 versus 8 injections). The results of these experiments 
are summarized in figures 10 and 11. Ampicillin treatment with an 
increased frequency and number of injections in combination with an 
increased daily dose, (12 injections of 25 mg/mouse every 8 h), 
apparently sterilized spleens a~d livers of most nude mice (Fig. 10). 
However, although the numbers of bacteria cultured from spleen and 
liver were significantly lower compared to untreated controls (Wilcoxon 
rank-sum test, P= 0.008) fifteen days after the termination of the 
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Fig. 8. Growth curves of Listeria monocytogenes in spleens and Zivers 
after intravenous inoaul.ation of 105 bacteria into normal (nu/+) mice 
which received ampicillin therapy 8 injections of 5 mg/mouse every 
12 h stai'ting a:t 36 h (-·-) a:nd untreated eontroZs (-). Eac:h point 
represents the mean and ranges of five mice (linear> scale). 
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Fig. 9. Growth curves of Listeria monocytogenes in spleens and livers 
after intmvenous inoculation of 105 bacteria into nude (nu/nu) rrrice 
whic:h rec:eived ampic:iZZin therapy 8 injec:tions of 5 mg/mouse every 
12 h starting a:t 36 h (-·-), a:nd untreated c:ontroZs !---!. Eac:h point 
represents the mea:n a:nd ranges of five mice (Zinear sc:aZe). 
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Fig. 10. G~owth curves of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 105 bacteria into nude (nu/nu) mice 
which received ampicillin therapy 12 injections of 25 mg/mouse every 
8 h starting at 36 h (-·-), and untreated controls (---). Each point 
represents the mean and ranges of five mice (linear seale). 
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Fig. 11. Growth curves of Li~teria monocytogenes in spleens and livers 
after intravenous inoculation of 105 bacteria into nude (nu/nu) mice 
which received ampicillin therapy 
16 injections of 5 mg/mouse every 12 h starting at 36 h (-·-), 
16 injections of 25 mg/mouse every 12 h starting at 36 h (---), 
32 injections of 25 mg/mouse every 12 h starting at 36 h ( ••• ), 
and untreated controls (---). Each point represents the mean and 
ranges of five mice (linear scale). 
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therapy, Listeria were still cultured from spleens and livers of all 
mice. The ampicillin sensitivity of the isolated bacteria was unchanged. 
One mouse out of 35 died within 19 days after inoculation. The excessive 
therapy of 32 injections of 25 mg ampicillin per mouse every 12 h was 
needed for complete recovery of nude mice (Fig. 11). With this therapy 
sterility of cultures of spleens and livers was maintained. 
Figure 12 shows the ampicillin serum levels after subcutaneous 
injections of ampicillin doses of 5 mg/mouse and 25 mg/mouse, determined 
in normal mice and nude mice. There were no substantial differences 
between the curves of serum ampicillin levels in nude mice and their 
littermates. Subcutaneous injections of 5 mg and 25 mg ampicillin gave 
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Fig. 12.· Serum eoncentPations of ampicillin aftep subcutaneous 
injections of 5 mg/mo"!ASe into normal (nu/+) mice (--) and n:ude 
(nu/nu) miee ( ..• ), and injeetions of 25 mg/mouse into normal 
(nu/+) miee (---) and nude (nu/nu) miee (-•--1. Eaeh point 
repPesents the mean of five mice ( + stanJ.a;r.d deviation). 
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rise to peak concentrations of 180 ~g/ml and 550 Mg/ml respectively; 
concentrations exceeding the MIC of Listeria for ampicillin i.e. 
0.16 ~g/ml, were present for about 3~ hand 5 h respectively. The serum 
concentrations of ampicillin after subcutaneous injections of 5 mg and 
25 mg ampicillin during the course of listeric infection, were the same 
for uninfected mice and infected mice. 
Discussion 
Listeria monocytogenes is a facultative intracellular bacterial 
parasite that can survive and multiply in macrophages (20) particularly 
in the spleen and liver. Resistance to infection caused by Listeria 
monocytogenes has been studied extensively by Mackaness and coworkers. 
It is clear that host resistance to listeric infection correlates with 
the capacity to develop cellular immunity, induced specifically by a 
T-cell mediated reaction. These sensitized T-lymphocytes are able to 
activate macrophages. Activated macrophages possess a number of 
remarkable properties including a greatly enhanced capacity for 
phagocytosis and destruction of Listeria monocytogenes (3, 16, 20, 21, 
34). Based upon these studies thymus-less animals are expected to have 
impaired host defense mechanisms against infection caused by Listeria 
monocytogenes. In our experiments we used mice homozygote for the 
mutation "nude" (nu/nu) which are described as deficient in thymus and 
thymus-derived (T) lymphocytes (15). Congenitally athymic nude (nu/nu) 
mice and their littermates, heterozygote for the mutation nude (nu/+) 
and immunologically normal, were challenged with different numbers of 
Listeria monocytogenes cells. The course of the infection ,..1as 
investigated by determining the number of Listeria in their spleens, 
livers and blood. The curves of bacterial multiplication in the spleen 
and liver and the outcome of infection (mortality or recovery) in nu/+ 
mice, differ with different numbers of inoculated bacteria. Normal mice 
developed a short-term listeriosis. Nude mice developed a chronic 
infection independent of the inoculum, with no signs of illness. Nude 
mice were able to restrain bacterial population - in fact their 
resistance was superior to that of normal mice - but were unable to 
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eradicate the infection. The course of listeric infection of nude mice 
and their littermates, as seen in our experiments, confirm the findings 
of other investigators (5, 7, 24, 30). Emmerling showed that in nude 
mice no significant changes in Listeria spleen counts occurred during 
35 days after bacterial challenge. During the initial phase of 
infection nude mice were capable of resisting the number of Listeria 
which killed normal mice. This enhanced resistance to infection of 
nude mice in the time period before a specific immune response 
developed, was evidently nonspecific. Large numbers of macrophages 
with enhanced bactericidal properties are supposed to exist in 
these mice lacking functional T-cells before the introduction of 
Listeria organisms (7). 
Ampicillin in large doses effectively cured normal mice from listeric 
infection. Studies by other investigators whose experiments differ in 
route of infection and bacterial inocula, also revealed that high doses 
of ampicillin are required to cure experimental listeric infections 
(8, 28, 31, 33). Ampicillin therapy that was adequate to cure normal 
mice, showed a complete loss of efficacy in the nude mice. Intensifica-
tion of the ampicillin treatment in terms of an increase in dose (5-10 
times) and/or frequency (8 h instead of 12 h) and/or number of 
injections (4 times) was not able to cure nude mice infected with 
5 x 105 Listeria. When the inoculum was lowered to 105 Listeria it 
remained extremely difficult to cure nude mice. A treatment schedule of 
not less than 32 injections of 25 mg ampicillin per mouse every 12 h 
was required for recovery. Ampicillin serum levels exceeding 500 ~g/ml 
were observed with this therapy. 
We may conclude from these experiments that loss of efficacy of 
antibiotic therapy resulted from impaired host defense mechanisms 
against the infectious organisms. Obviously killing of these intra-
cellular bacteria in normal mice is due to the combined effect of the 
curative action of the antibiotic and the activity of the cellular 
defenses of the host. Lack of cellular immunity can not be compensated 
by intensification of the ampicillin treatment schedule. ~icillin 
treatment failure because of the development of antimicrobial 
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resistance is not likely, because of the fact that bacteria isolated 
from nude mice after extensive ampicillin treatment retained their 
ampicillin sensitivity. Therefore two possibilities may account for the 
survival of phagocytized Lister-ia when serum ampicillin levels are 
high. First, the antimicrobial drug does not penetrate phagocytic cells 
and thus does not reach the bacteria in their intracellular location. 
Secondly, the metabolic activity of the intraleukocytic bacteria in 
nude mice is low so that they are not susceptible to drug action. In 
vitro studies suggest that ampicillin penetrates poorly into cells 
(4, 18). Our experiments also suggest a poor penetration of phagocytes 
by ampicillin as high doses of ampicillin were needed for complete 
recovery of normal mice. However, it must be realized that inhibitory 
ampicillin serum levels were present only during part of the dosage 
interval due to the short serum half-life of ampicillin in mice. Never-
theless, an intensified treatment (increased frequency of injections in 
combination with an increased ampicillin dose and number of injections) 
was only partly successful in nude mice. That ampicillin treatment was 
successful in normal mice might suggest that loss of ampicillin 
activity in nude mice is not only due to lack of penetration of the 
phagocyte by the antibiotic. Some evidence to support the hypothesis 
of low metabolic activity of the intraleukocytic bacteria might be 
inferred from the Listeria counts in spleen and liver from nude mice, 
these counts suggest no bacterial multiplication in spleen and liver. 
It must be realised, however, that from total viable counts of spleen 
and liver, it can not be concluded whether these curves reflect a 
chronic infection or are a composite of extracellular multiplication 
and intracellular killing of the organisms. 
With the object to investigate the reason for the failure of ampicillin 
therapy to cure listeric infections in the compromised host, these 
studies will be continued. Other antibiotics will be applied in this 
experimental infection model, especially antibiotics which differ from 
ampicillin in cell-permeability and serum half-life. 
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Chapter 6 
GENERAL DISCUSSION 
The relation between host defense mechanisms and the efficacy of 
antibiotic therapy of bacterial infections has been studied in this 
thesis. Because the critical role of individual host defense factors 
in the process of recovery during antimicrobial therapy can not be 
established easily in clinical situations, we resorted to an 
experimental approach. Animal models of experimental infections with 
S. pneumoniae and L. monocytogenes in rats and mice were used. The 
host-bacteria relationship with these two microorganisms is relatively 
well-understood but completely different. This enabled us to evaluate 
the change in efficacy of antimicrobial therapy as a function of 
selective elimination of several forms of host defense. The results 
were compared with the response to antimicrobial therapy of infections 
in normal animals. 
Phagocytic cells such as circulating polymorphonuclear leukocytes (PMN) 
or fixed macrophages of the spleen, are primarily important for host 
defense against bacterial infection. Phagocytosis of Streptococcus 
pneumoniae involves interaction between bacteria and PMN's, where 
components of the complement system promote attachment of bacteria to 
phagocytic cell membranes before opsonizing antibodies develop (10, 11). 
The spleen also participates in clearing Streptococcus pneumoniae from 
the blood s·tream. Host resistance to Listeria monocytogenes, however, 
depends on a T-cell mediated reaction resulting in activation of 
macrophages, the target cells of Listeria (6, 12). Defects in phagocytic 
activity as a consequence of low serum opsonic levels correlate with 
the occurrence of infections by bacteria with polysaccharide mucoid 
capsules, such as Streptococcus pneumoniae. In that case pneumococcal 
clearance from the blood stream is dependent on optimal splenic 
function (2). Defects in T-cell mediated functions are associated with 
an increased incidence of infections due to bacteria such as 
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Listeria monocytogenes, which are located intracellularly in macro-
phages (8). 
Chapters I through 3 show the importance of intact host defense 
mechanisms for successful antimicrobial therapy of pneumococcal pneumo-
nia. This was studied in normal rats and in rats treated with cobra 
venom factor. This factor was used to suppress the phagocytosis by PMN 
of Stpeptococcus pneumoniae as a result of complement depletion. From 
the studies described in Chapter 1 it appeared that, compared to normal 
rats, the spreading of the pneumococcal infection was more rapid and 
extensive in rats with inadequate phagocytosis of the pneumococci. In 
man abnormalities in the alternate complement pathway, are also known 
to be associated with increased susceptibility to pneumococcal infec-
tions (9). Pneumococcal pneumonia in rats with intact host defense 
mechanisms could be successfully cured by low doses of penicillin or 
clindamycin (Chapters 1 and 3). The efficacy of both antibiotics- in 
terms of minimal dosage and treatment schedule required for complete 
recovery - was equal. The antimicrobial treatment schedule with peni-
cillin or clindamycin which cured normal rats, was not successful in 
eradicating the pneumococcal infection in rats with impaired phagocytosis 
(Chapters 1 and 3). Therefore we investigated to what extent the 
therapeutic effect of the antibiotic therapy in these rats could be 
restored by alterations in the treatment schedule. Observations related 
to the dose and administration schedule of penicillin and clindamycin 
are reported in respectively Chapter 2 and Chapter 3. The increase in 
dosage required for the successful treatment of pneumococcal infection 
in rats with impaired phagocytosis was considerably greater for peni-
cillin (25-fold, or 17-fold in combination with a shortened interval 
between injections) than for clindamycin (4-fold). This observation 
could not be explained by a difference in in vitro sensitivity of the 
pneumococcal strain for both antibiotics, nor by inactivation of peni-
cillin by inflammatory exudate at the site of infection (Chapter 3). 
The results might, however, be explained on the basis of a distinct 
pharmacological behavior of both antibiotics as expressed by substantial 
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differences in peak values and serum half-life values of the drugs. 
It was therefore concluded that in normal rats, antimicrobial treatment 
schedules with periodically subinhibitory serum levels were apparently 
sufficient to eradicate pneumococcal infection in the lung. On the 
other hand in rats with extensive pulmonary lesions due to impaired 
phagocytosis of pneumococci, it was absolutely essential to maintain 
prolonged effective serum levels during the whole treatment period. 
Presumably such a treatment schedule is required to achieve effective 
antibacterial levels at the site of infection. 
Another form of impaired host defense to pneumococcal infection i.e. 
removal of the spleen, was studied in chapter 4. As is known from 
clinical studies, the risk of postsplenectomy pneumococcal sepsis is 
increased in children under 3 years of age, in patients with hematologic 
disorders and in patients who received chemotherapy for malignancies 
such as Hodgkin's disease (2, 4). In these patients the underlying 
disease itself is associated with increased susceptibility to 
infection. This in turn predisposes the patient to overwhelming and 
frequently fatal infection with pneumococci or other pathogens when 
the spleen is removed. Increased susceptibility to pneumococcal 
infection appears to be correlated with a reduced ability to remove 
pneumococci circulating in the blood. This may be the consequence of 
low serum opsonic levels, as found in young individuals and in adults 
with complement deficiences or an impaired antibody response. In the 
animal studies of Chapter 4, experimental conditions similar to 
clinical situations were chosen. The age at the time of splenectomy 
and the opsonic capacity of the serum were introduced as variables. 
Increased susceptibility to intravenous pneumococcal infection after 
splenectomy was demonstrated in rats at young age and in adult rats 
with deficient serum opsonic capacity. Splenic phagocytosis of pneu-
mococci appeared to be critically important in the face of a 
quantitative deficiency in opsonins. In these specific groups of rats 
penicillin therapy which could cure pneumococcal infection in 
non-splenectomized rats, had lost its effectiveness. The effect of 
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the penicillin therapy could be restored by an increase in daily 
penicillin dose of four times in splenectomized young rats, of 20 times 
in adult rats with low serum opsonic levels, and of 100 times in 
splenectomized adult rats with low serum opsonic levels. The observa-
tions suggested the existence of a relationship between a need for 
an increased penicillin dose and an increased bacteria count in the 
blood. 
In Chapter 5 we examined the importance of intact host defense 
mechanisms for successful antimicrobial therapy of infections caused 
by Listeria monocytogenes. Cell-mediated immune responses play a major 
role in host defense against these facultative intracellular bacteria, 
induced specifically by a T-cell mediated reaction. These sensitized 
thymus-dependent lymphocytes activate macrophages harboring the 
Listeria resulting in destruction of the bacteria. Thymus-less (nude) 
mice have impaired host defense mechanisms against infections caused 
by Listeria monocytogenes. The effect of impaired cell-mediated 
immunity upon the course of the infection and the efficacy of ampicil-
lin therapy, was therefore studied in thymus-less nude mice and their 
littermates. Experimental infections were produced with different 
numbers of Listeria. Normal mice developed short-term listeriosis the 
course of which depended upon numbers of inoculated bacteria. Nude 
mice developed a chronic infection independent of the inoculum. 
Although the animals demonstrated no signs of illness, they were not 
able to eradicate the Listeria infection. This corresponds with the 
clinical observation that infections due to opportunistic pathogens 
such as Listeria monocytogenes result from depression of cellular 
immune responses, and therefore may complicate lymphatic malignancy 
such as Hodgkin's disease, especially during intensive chemotherapy (8). 
Experiments described in Chapter 5 revealed that ampicillin in large 
doses effectively cured normal mice from listeric infection. The same 
ampicillin treatment was completely ineffective in mice with impaired 
host defense mechanisms. Intensification of ampicillin treatment 
schedules could not compensate for lack of cellular immunity. Antibiotic 
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treatment failure because of the development of antimicrobial resistance 
is not a likely explanation, because of the fact that bacteria isolated 
from mice after extensive ampicillin treatment retained their ampicil-
lin sensitivity. Therefore two possibilities may account for the 
survival of phagocytized Listeria in animals with impaired host defense. 
First, ampicillin does not penetrate phagocytic cells and thus does not 
reach the bacteria in their intracellular location. Secondly, the 
metabolic activity of the intracellular bacteria is at such a low level 
that they are not susceptible to drug action. To see whether loss of 
ampicillin activity in nude mice is due to lack of penetration the 
effect of rifampicin to cure listeric infection in normal mice and 
nude mice was investigated in recent experiments (reported in the 
appendix). It is known that rifampicin is able to penetrate phagocytic 
cells (3, 5, 7) and has a longer serum half-life in mice than does 
ampicillin (serum half-life values of rifampicin and ampicillin in 
mice are 6 hand~ h respectively). Rifampicin in low dosage cured 
listeric infection in normal mice. If the treatment schedule was 
intensified in terms if a 40-fold increased dosage in combination with 
an increased number of injections (4 to 16 injections) this drug was 
also able to eradicate Listeria from nude mice. Thus the loss of 
cell-mediated immune functions could be compensated only by a treat-
ment schedule with long-term effective serum levels of an antimicrobial 
drug which is capable of penetrating into host cells. These results 
favor the second hypothesis of low metabolic activity of the intra-
leukocytic bacteria in the nude mice. Bacteria located within cells 
whose intracellular killing mechanisms fail to function, probably 
persist in a stationary phase. 
From our experimental studies in the animal host outlined in Chapters 
1 through 5, some basic conclusions on the relation between impaired 
host defense mechanisms and the efficacy of antimicrobial therapy can 
be drawn: 
Loss of activity of antimicrobial therapy results from selectively 
impaired host defense against the infectious organisms. This seems to 
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be true irrespective of whether the microorganism is a classice pathogen 
such a Streptococcus pneumoniae which produces disease by growing 
outside the polymorphonuclear leukocytes, or a microorganism such as 
Listeria monocytogenes that belongs to the endogenous flora, multiplies 
within macrophages and causes serious infection in hosts lacking normal 
defense mechanisms. Obviously the total effect of antimicrobial therapy 
is the combined effect of the curative action of the antimicrobial 
drug and the activity of the cellular defenses of the host. 
Whether lack of host defense functions can be compensated by 
intensification of the antibiotic treatment schedule, i.e. by 
manipulating the dose and/or frequency of administration, seems to 
depend on the infectious agent (obligatory extracellular parasite or 
facultative intracellular parasite) and on the experimental infection 
(acute inflammatory response or chronic infection). In the case of 
pneumococcal infections, lack of PMN phagocytic activity either with 
or without lack of splenic functions can be compensated by considerable 
increase in antibiotic dosage. In pneumococcal pneumonia with extensive 
pulmonary lesions due to impaired phagocytosis, antimicrobial treat-
ment schedules that give rise to prolonged inhibitory antibiotic serum 
levels in the interval between two successive injections, are of prime 
importance. In the case of listeric infections, lack of cell-mediated 
immunity can be compensated only by a treatment schedule with long-term 
inhibitory serum levels of an antimicrobial drug which is capable of 
penetrating into host cells. Low metabolic activity of the intra-
leukocytic bacteria in the immunodeficient host may possibly account 
for failure of conventional antimicrobial therapy. 
In these experimental studies in animals with compromised defense 
systems, the critical role of host defenses in antimicrobial treat-
ment has been demonstrated. Evidence is presented that selectively 
impaired host defense mechanisms may result in a subtantial loss of 
efficacy of antimicrobial therapy. Successful treatment of bacterial 
infection in the compromised host must not only be based upon 
characterization of the infecting organism in terms of species and in 
vitro sensitivity to antibiotics, but also the judicious use of 
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antibacterial agents is essential. In this respect it is of prime 
importance to maintain effective antibiotic concentrations of the drug 
at the site of infection. 
These studies support clinical data suggesting that the schedule of 
drug administration may play an important role in the outcome of 
antibiotic therapy in patients with impaired host defense mechanisms 
(I) • 
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APPENDIX 

Rifampicin therapy of normal (nu/+) mice and nude (nu/nu) mice after 
inoculation of 5 x 105 Listeria monocytogenes 
Four injections of 0.024 mg rifampicin per mouse every 24 h, starting 
36 h after initiation of the infection, could sterilize spleen, liver 
and blood of all normal mice within 14 days after bacterial inocula-
tion (Fig. 1). This rifampicin treatment was unable to cure nude mice 
infected with the same number of Listeria (Fig. 2). To cure the nude 
mice the rifampicin treatment was intensified by two-fold increases 
of the daily dose of rifampicin (0.024 mg to 1.92 mg/mouse) or by 
increasing the daily dose in combination with an increased number of 
injections (4 to 16 injections). By increasing the number of injections 
(to 16) as well as the daily dose (to 0.96 mg) rifampicin could cure 
the nude mice (Fig. 3). 
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Fig. I. Growth curves of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 5 x 105 bacteria into nonmal (nu/+) 
mice which received 4 injections of 0.024 mg rifampic~n per mouse 
erJery 24 h starting at 36 h (---), a:nd untreated controls c--). Each 
point represents the mean and ranges of five mice (linear scale). 
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Fig. 2. Growth curves of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 5 x 105 bacteria into nude (nu/nu) 
mice which received 4 injections of 0.024 mg rifampicin per mouse 
every 24 h starting at 36 h (---), and untreated controls (---). Each 
point represents the mean and ranges of five mice{Zinear scale). 
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Fig. 3. Growth curves of Listeria monocytogenes in spleens and livers 
after intravenous inoc."U.Zation of 5 x 105 bacteria into nude {nu/n:u) 
mice which received 16 injections of 0.96 mg rifampicin per mouse 
every 24 h starting at 36 h ( ... ),and untreated controls (---). Each 
point represents the mean and ranges of five mice (linear scale). 
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Rifampicin therapy of normal (nu/+) mice and nude (nu/nu) mice after 
inoculation of 105 Listeria monocytogenes 
0 
Four injections of 0.012 mg rifampicin per mouse every 24 h, starting 
36 h after initiation of the infection, could sterilize spleen, liver 
and blood of all normal mice within six days after bacterial inocula-
tion (Fig. 4). This rifampicin treatment was unable to cure nude mice 
infected with the same number of Listeria (Fig. 5). To cure the nude 
mice the rifampicin treatment was intensified by two-fold increases 
of the daily dose of rifampicin (0.012 to 1.92 mg/mouse) or by 
increasing the daily dose in combination with an increased number of 
injections (4 to 16 injections). By increasing the number of injections 
(to 16) as well as the daily dose (to 0.96 mg) rifampicin could cure 
the nude mice (Fig. 6). 
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Fig. 4. Growth curves of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 105 bacteria into normal (nu/+) mice 
which received 4 injections of 0. 012 mg rifampic-in per mouse every 
24 h starting at 36 h (---), and untreated eontroZs (---). Eaeh 
point represents the mean a:nd ranges of five mice (linear seale). 
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Fig. 5. Growth c~rves of Listeria monocytogenes in spleens and livers 
after intravenOus inoculation of 105 bacteria into nude (nu/nu) mice 
which received 4 injections of 0.012 mg rifampicin per mouse every 
24 h starting at 36 h (----), and untreated controls (--). Each point 
represents the mean and ranges of five mice (linear seale). 
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Fig. 6. Growth c~es of Listeria monocytogenes in spleens and livers 
after intravenous inoculation of 105 bacteria into nude (nu/nu) mice 
which received 16 injections of 0.96 mg rifampicin per mouse every 
24 h starting at 36 h !·····), and untreated controls (--). Each point 
represents the mea:n and ranges of five mice (linea:t> seale). 
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Fig. 7. Serum concentrations of rifampicin after subc~taneous 
injections of 0.024 mg/mouse into normal (nu/+) miee (--) and 
nude {nu/nu) mice (-·-·-) 3 0.012 mg/mouse into normal mice (---) 
and nude mice (--·-) and 0.96 mg/mouse into nomaZ nrice (-} 
and nude mice ~--~- Each point represents the mean of five 
mice (:!:._ standa:t'd deviation) (linear scale). 
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Fig. 8. Serum concentrations of rifampicin and ampiciZZin. Noz.maZ 
(nu/+) mice were injected subcutaneously-with rifampicin doses of 
0.024 mg/mouse (---), 0.012 mg/mouse (--)and 0.96 mg/mouse ( ..... )or 
with ampic~ZZin doses of 5 mg/mouse !-·-) and 25 mg/mouse (---). Eaeh 
point rep"!'esents the mean of five mice (+standard deviation). These 
data show that subc~taneoui injections of ~fampicin and ampicillin 
gave rise to completely different ser7hn levels in the mice with 
regard to duration of adequate Zevels. Sepym antibiotic levels above 
the minimal f-n,hibito"Y'y concentration (MIC) for Listeria monocytogenes 
were maintained for> a nruch Zanger period with r•ifcunpic:in than with 
ampic~llin. AcRAaZZy~ during the interval between two injections of 
0. 024 mg r>ifampicin per> mouse-3 ser'Um levels wer-e 2.3-24 h above or 
equal to the MIC of L. monocytogenes to rifampicin (0.04 ~g/ml); serum 
concentrations exceeding the MIG for L. monocytogenes to ampicillin 
(0.16 "g/mZ) wer•e present for about 3"' and 5 h if treatment with 
ampicillin doses of r-espectively 5 mg and 25 mg per mouse was applied. 
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SUMMARY 
This thesis deals with the evaluation of the change in efficacy of 
antimicrobial agents in the treatment of experimental infection in rats 
and mice with selectively impaired host defense mechanisms. 
As outlined in the General Introduction patients with impaired host 
defense mechanisms due to malignant disease or its treatment (radio-
therapy, chemotherapy) have a high degree of infectious complications. 
These may be difficult to cure as antimicrobial therapy that is 
usually effective in the normal host, may be inadequate in patients 
with seriously compromised host defenses. Therapeutic failures occur 
despite the organisms usual sensitivity. In these patients the 
initial loss of host resistance is related to the underlying disease 
or brought about by the antineoplastic therapy, resulting in a marked 
reduction in number or function of polymorphonuclear leukocytes (PMN), 
decreased antibody formation or suppressed cellular immune reactions. 
Two questions arise. To what extent does the susceptibility to 
infections and the efficacy of antimicrobial therapy depend on host 
defense mechanisms? And secondly, can lack of host defense functions 
be partially compensated by intensification of the antibiotic treatment 
schedule. As it is difficult to delineate the change in efficacy of 
antimicrobial therapy as a function of specific defects in host 
defense in clinical studies, these problems were investigated by an 
experimental approach. The animal studies described in chapters 1 
through 5 provide some relevant information with regard to these 
questions. Models of experimental infections with S. pneumoniae 
and L. monoeytogenes in rats and mice were used. Because the 
host-bacteria relationship with these two microorganisms is relatively 
well-understood but completely different, we were able to study the 
effect of elimination of several forms of host defense upon the 
activity of antimicrobial therapy. 
Chapters 1 through 3 deal with the critical role of phagocytosis by 
PMN's in relation to antimicrobial therapy of pneumococcal pneumonia 
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in rats. From these studies it can be concluded that impaired 
phagocytosis of the pneumococci by PMN's results in loss of efficacy 
of antimicrobial treatment by penicillin or clindamycin. Loss of PMN 
phagocytic activity can be compensated by an intensified antibiotic 
treatment schedule in terms of a considerable increase in dosage and 
an increased injection frequency. For treatment of pneumococcal pneu-
monia in rats with extensive pulmonary lesions due to impaired 
phagocytosis of pneumococci, the choice of an antimicrobial agent is 
not only determined by the in vitro sensitivity of the infecting 
organism for the antimicrobial drug, also the pharmacological properties 
of the drug appear to be critical. Treatment schedules that give rise to 
prolonged inhibitory antibiotic serum levels in the interval between two 
successive injections are of prime importance. 
Chapter 4 reports on the effects of splenectomy upon the course 
of pneumococcal bacteremia in rats, and the efficacy of penicillin 
therapy. From these experiments it can be concluded that increased 
susceptibility to intravenous pneumococcal infection and loss of 
efficacy of penicillin treatment results from splenectomy in young rats 
and in adult rats with minimal serum opsonic levels. In these specific 
groups of rats, the capacity to remove circulating pneumococci from the 
blood is reduced. Penicillin treatment which can prevent mortality of 
rats with intact spleens, has lost its activity in these groups of rats. 
A considerable increased amount of antibiotic can compensate for lack 
of splenic functions. 
In chapter 5 the critical role of T-cell mediated immunity in relation 
to antimicrobial therapy of intracellular listeric infection in mice 
is studied. These experiments reveal the occurrence of chronic listeric 
infections in animals with impaired T-cell mediated immunity. Ampicillin 
treatment which can cure normal mice, has lost its activity. Even 
excessive ampicillin treatment schedules are not able to cure the 
listeric infection in the mice with impaired T-cell functions. In recent 
experiments (described in the appendix) infected nude mice were treated 
with rifampicin which has a better cell penetrating capacity and a 
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longer serum half-life in mice than does ampicillin. From these studies 
it appears that prolonged rifampicin treatment in high doses is able to 
eradicate listeric infection in nude mice. Thus, lack of T-cell mediated 
immunity can only be compensated by a treatment schedule with long-term 
effective serum levels of an antimicrobial drug which is capable of 
penetrating into host cells. 
A general discussion of the "results of our experimental studies is 
presented in chapter 6. 
In these experimental studies in animals whose basic defense systems 
have been compromised in various ways, evidence is presented that 
selectively impaired host defense mechani~ms may result in a 
substantial loss of efficacy of antimicrobial therapy. Successful 
treatment of infection in the compromised host not only depends on 
the isolation of the causing organism and the estimation of its 
susceptibili.ty to antibiotics, but also on the judicious use of 
antibacterial agents. In this respect the maintenance of effective 
levels of the drug at the site of infection appears to be of prime 
importance. 
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SAMENVATTING 
Met het dierexperimenteel onderzoek, beschreven in dit proefschrift, 
wordt getracht meer inzicht te geven in de relatie tussen afweerfactoren 
en de werkzaamheid van antibiotica bij het bestrijden van bacteriele 
infecties. 
In de klinische geneeskunde wordt men in toenemende mate geconfronteerd 
met patienten die lijden aan aanwijsbare vormen van weerstandsverminde-
ring, bijvoorbeeld als gevolg van maligniteiten en de behandelingen 
daarvan (bestraling of chemotherapie). Ernstige infekties komen als 
gevolg hiervan frekwent voor en hebben niet zelden een fataal verloop 
omdat de antimicrobiele therapie die werkzaam is bij de normal_e gast-
heer, in deze patienten vaak geheel of gedeeltelijk faalt. Verschillende 
factoren dragen gelijktijdig bij aan de vermindering van de weerstand. 
Maligniteiten en chemotherapeutische behandelingen kunnen aanleiding 
geven tot onderdrukking van humorale of cellulaire immuniteit, alsook 
vermindering van het aantal of de funktie van polymorphonucleaire 
leukocyten (PMN). Een tweetal vragen komcn naar voren. Ten eerste, 
in welke mate is de werkzaamheid van een antibioticum therapie afhanke-
lijk van weerstandsfactoren van de gastheer? Ten tweede, kan een ver-
zwaring van het antibioticum therapieschema het gemis aan eigen afweer-
factoren geheel of gedeeltelijk compenseren? Omdat de klinische situatie 
weinig ruimte biedt voor de bestudering van deze vragen, is gekozen 
voor een dierexperimentele benadering waarbij het mogelijk is weer-
standsfactoren selectief weg te nemen. Door m.iddel van de studies be-
schreven in de hoofdstukken 1-5 proberen wij een bijdrage te leveren 
aan de beantwoording van deze vragen. Door de keuze van de experimentele 
infecties, veroorzaakt door Streptococcus pneumoniae of Listeria mono-
cytogenes, was het mogelijk de relatieve betekenis van afweerfactoren 
afzonderlijk voor de werkzaarnheid van antibiotica te bestuderen. 
De hoofdstukken I-3 beschrijven een experimentele pneumococcen pneumonie 
bij de rat. In dit model is het belang van intacte afweerfactoren voor 
het welslagen van antimicrobiele therapie bestudeerd. Aangetoond is 
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dat de antimicrobiele behandeling door penicilline of clindamycine, die 
wel normale dieren kan genezen, faalt als gevolg van een verminderde 
phagocytose door PMN van pneumococcen. Het verlies van pneumococcen-pha-
gocyterend vermogen door PMN kan grotendeels gecompenseerd worden door 
een verzwaring van het antibioticum behandelingsschema in de vorm van 
een dosisverhoging, al dan niet in combinatie met een verhoogde injec-
tiefrekwentie. Omdat het hierbij gaat om de behandeling van een zich 
snel-verspreidende longinfectie als gevolg van inadekwate phagocytose, 
dient bij de keuze van een antibioticum niet aileen gelet te worden op 
het antibioticum-gevoeligheidspatroon van de verwekker, maar ook op de 
pharmacologische eigenschappen van het middel. Behandelingsschema's 
die langdurig-werkzame antibioticum serumspiegels geven tussen twee 
opeenvolgende injecties zijn van het grootste belang. 
Hoofdstuk 4 bespreekt de gevolgen van splenectomie voor het verloop van 
een pneumococcen bacteriaemie in ratten enerzijds, anderszijds de werk-
zaamheid van een penicilline therapie. Deze experimenten laten zien dat 
het wegnemen van de milt resulteert in een verhoogde mortaliteit als 
gevolg van de intraveneuze pneumococcen infectie in ratten op jonge 
leeftijd, en in volwassen ratten die al een verhoogde pneumococcen-
infectiegevoeligheid hadden als gevolg van een verminderd pneumococcen-
opsonizerend vermogen van het serum. De verhoogde gevoeligheid voor 
infectie blijkt gecorreleerd te zijn met een gereduceerd vermogen om 
circulerende pneumococcen uit het bloed te verwijderen. In deze twee 
groepen van dieren heeft de behandeling met penicilline die nodig is om 
sterfte van niet-gesplenectomeerde ratten te v66rkomen, zijn werkzaamr 
heid verloren. Een aanzienlijke verhoging in penicilline doses kan het 
gemis aan miltfunkties compenseren. 
In hoofdstuk 5 wordt het belang van cellulaire immuniteit in relatie tot 
de antimicrobiele therapie van intracellulaire Listeria infecties bij 
muizen bestudeerd. Deze experimenten tonen aan dat de infectie met 
L. monoeytogenes in dieren met verminderde T-cell funkties een chronisch 
verloop heeft; in deze muizen heeft de behandeling met ampicilline die 
muizen met een intacte afweer kan genezen, zijn werkzaamheid verloren. 
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Zelfs behandelingsschema's met frekwente injecties van hoge doses ampi-
cilline zijn niet in staat de Listeria infectie in de muizen met ver-
minderde cellulaire immuniteit te genezen. In recente experimenten 
(beschreven in de appendix) zijn de geinfecteerde muizen behandeld met 
rifampicine~ een antibioticum dat een beter cel-penetrerend vermogen en 
een langere serum half-waarde tijd heeft dan ampicilline. Uit deze 
studies blijkt dat een langdurige behandeling met rifampicine in hoge 
doses in staat is de Listeria infectie in de muizen met verminderde 
afweer te beeindigen. Blijkbaar kan gemis aan cellulaire immuniteit 
slechts gecompenseerd worden door een behandelingsschema met langdurig-
werkzame serumspiegels van een antibioticum dat het vermogen heeft in 
gastheercellen binnen te dringen. 
In hoofdstuk 6 worden de resultaten van deze experimentele studies be-
sproken in een algemene discussie. Geconcludeerd wordt dat voor een 
succesvolle behandeling van infecties een samenspel van twee componenten 
vereist is, te weten intacte afweerfactoren en gerichte, adekwate 
toediening van antibiotica. Selectieve vermindering van afweermechanis-
men resulteert in een substantieel verlies van werkzaamheid van 
antimicrobiele therapie. Wanneer de afweermechanismen van de gastheer 
niet meer intact zijn, is succesvolle behandeling van infecties niet 
alleen afhankelijk van de isolatie van de verwekker en het bepalen van-
het antibioticumgevoeligheidspatroon daarvan, maar ook van het zorg-
vuldig gebruik van antimicrobiele middelen. In dit opzicht is het van 
het grootste belang dat werkzame concentraties op de plaats van de 
infectie gehandhaafd worden. 
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